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Abstract

Chronic diabetic complications are significant causes of morbidity. In
diabetes, as the cellular changes are similar to aging, we investigated the role of
sirtuins (SIRTs) in chronic diabetic complications.
We examined glucose and aging-induced changes in the endothelial cells
(ECs), the primary targets of chronic diabetic complications. ECs in high glucose
showed evidences of early senescence, being more pronounced in microvascular
ECs in association with decreased SIRT1 and FOXO1-dependent reduction in
antioxidant gene expressions. A regulatory relationship of deacetylator SIRT1 and
histone acetylator p300 was identified. Renal and retinal tissues of diabetic animals
showed similar results.
Having established such changes, we investigated microRNA-mediated
regulation of glucose-induced SIRT1 alteration. We examined the effect of miRNA195 (miR-195), a SIRT1-targeting miRNA, on the development of diabetes-induced
changes in the ECs and retina. High glucose caused increased miR-195 levels and
decreased SIRT1 expression in the ECs. We showed that miR-195 binds to the 3′
untranslated region of SIRT1 and transfection with miR-195 antagomir or overexpression of SIRT1 prevented above changes, whereas transfection with miR-195
mimic produced glucose-like effects.

miR-195 expression was upregulated in

retinas of diabetic rats and intravitreal injection of miR-195 antagomir ameliorated
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reduction of SIRT1 and associated changes in diabetes. These studies identified a
novel mechanism whereby miR-195 regulates SIRT1-mediated tissue damage.
Based on results above, we examined whether in diabetes, SIRT1 alteration
mediate specific effects in the target organs affected in diabetic complications. We
focused on endothelin1 (ET-1) and transforming growth factor beta 1 (TGF-β1), two
key mediators of increased extracellular matrix protein production. In ECs exposed
to high glucose, there were increased ET-1, TGF-β1, p300 and collagen Iα(I) along
with SIRT1 downregulation. Such changes were corrected by knockdown of p300 or
SIRT1 overexpression. In the kidneys and retina of diabetic mice, similar
biochemical alterations were seen along with increased vascular permeability in
retina and microalbuminuria of the kidney. In the transgenic animals with SIRT1
overexpression, such diabetes-induced abnormalities were prevented.
Overall

these

studies

identified

SIRT1-mediated

accelerated

aging

phenomena in diabetes causing cellular injuries leading to renal and retinal injury.
SIRT1 may lend itself as a target to prevent organ damages in diabetes.

Keywords
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complications, Diabetic retinopathy, Diabetic nephropathy, Cellular aging
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Chapter 1

1

1.1

Introduction

Diabetes mellitus (epidemiology and its economic impact)
Diabetes mellitus (DM) is a multifactorial and genetically heterogeneous

disease which is characterized by impaired glucose homeostasis, reduced insulin
activity and insulin resistance leading to elevated blood glucose levels [1, 2]. The
elevated blood glucose causes symptoms of frequent urination, increased thirst
and hunger in patients [1, 2].
As of 2013 it is estimated that 382 million people worldwide have diabetes
[3-8]. This is affecting in equal rates in both men and women [3-8]. Diabetes
related complications are the 8th leading cause of death worldwide and half the
people who die from diabetic complications are under the age of 60 [3-8]. By
2035, the number of people with diabetes is predicted to rise to 592 million [3-8].
Diabetes occurs throughout the world, but is more predominant in the developed
countries (specially type 2). However the greatest increase in rates is expected to
occur in the developing countries in Asia and Africa [3-8]. Such increase in rates
in developing countries is probably due to urbanization and lifestyle changes,
specially a western-style diet. This suggests an environmental effect, but there is
little understanding of such mechanism at present [3-8]. According to
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International Diabetes Federation, the economic cost of diabetes globally in 2013
was estimated to be $548 billion [8]. In Canada, according to data from the Public
Health Agency (PHA) of Canada's Economic burden of illness in Canada (EBIC)
the estimated cost for diabetes cares is above $7 billion per year [9, 10].
There are three main types of DM. Type 1 DM, type 2 DM and gestational
DM.

1.1.1 Type 1 DM
Type I DM results from the body's failure to produce insulin and was
previously referred to as insulin-dependent diabetes mellitus (IDDM) or juvenile
diabetes [1, 2]. Type 1 DM is caused by autoimmune destruction of the insulin
producing beta cells in the pancreatic islets. The subsequent loss of insulin
causes hyperglycemia [1, 2]. These patients require exogenous insulin injections
for survival [1, 2].

1.1.2 Type 2 DM
Type 2 DM (previously known as non-insulin dependent diabetes mellitus,
NIDDM) results from resistance to insulin [1, 2]. This is a condition in which cells
fail to use insulin properly and sometimes also with an absolute insulin deficiency
[1, 2]. This typically develops in adults. The etiology of type 2 diabetes is
unknown. However, physiological, genetic and environmental factors such as
obesity, family history, pollution are known to predispose someone to this
disease [1-10]. Most of the population with diabetes belongs to this group [1-10].
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1.1.3 Gestational DM
Gestational diabetes occurs in some pregnant women, without a previous
history of diabetes during third trimester. This is caused by impaired function of
the insulin receptors due to interference with pregnancy related hormones
leading to high blood glucose level [1, 2]. GDM usually resolves after the birth of
the baby however these patients have a high risk of developing type 2 DM later
in life [1, 2].

1.2

Diabetic complications
Despite the etiologic type of diabetes, chronic hyperglycemia in advanced

form of the disease causes serious health problems affecting multiple organs
causing conditions such as retinopathy, nephropathy, cardiomyopathy, and
neuropathy [11]. Such damages to the eye, kidney, heart and nerves are caused
by micro- and macro vascular dysfunctions [12, 13]. Hyperglycemia causes
structural and functional alteration to the vascular system thus affecting the target
organs [11-13]. In the present study we have focused on diabetic retinopathy and
nephropathy.

1.2.1 Diabetic retinopathy (DR)
DR is a slowly progressive disease of the eye which if left untreated can
cause blindness [14]. Hyperglycemia induced oxidative stress in diabetes is the
primary stimuli that triggers a cascade of events leading to DR [14-17]. DR
causes vascular structural and functional changes in the retina. DR is classified
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into two phases, non-proliferative diabetic retinopathy (NPDR) and proliferative
diabetic retinopathy (PDR) [14-17]. In NPDR micro vessels in the retina become
weak and leaky forming microaneurysms and causing retinal hemorrhages,
which leads to decreased vision [14-16]. A characteristic feature of PDR is
neovascularization in which new blood vessels grow to reperfuse ischemic areas
of the retina [14-16]. These new fragile blood vessels hemorrhage easily and in
advanced stage cause scarring, tractional retinal detachment and eventually
blindness [14-16].

1.2.2 Diabetic nephropathy (DN)
DN is a progressive kidney disease caused by microangiopathy of the
kidney glomeruli [11, 12]. DN is characterized by nephrotic syndrome (increased
permeability of the capillary wall causing microalbuminuria, hypoalbuminemia,
hyperlipidemia and edema) and diffuse glomerulosclerosis [11, 12]. It is a major
cause of dialysis in Western countries [1-10]. In spite of the improvements in
therapeutic modalities, diabetes and its complications account for significant
morbidity and mortality throughout the world [1-10]. The root cause of all vascular
damage in chronic diabetic complication is endothelial cell (EC) dysfunction [1113].

1.3

Endothelial cell dysfunction
Endothelial dysfunction (ED) is the initiating and perpetuating factor in the

development of vascular complications [11-13]. Loss of proper endothelial
function is a characteristic feature of several vascular diseases. It is often
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regarded as a key early event in the development of atherosclerosis during early
stages of diabetes [11-13, 18, 19]. In diabetes, the most prevailing mechanism of
endothelial dysfunction is an increase in oxidative stress which can alter cellular
homeostasis via several mechanisms [12, 13]. In response to high ambient
glucose levels, several metabolic pathways get activated. These include the
polyol pathway, non-enzymatic formation of advanced glycation end-product
(AGE), activation of protein kinase C (PKC) and hexosamine pathway [12, 13]. It
has been shown that in diabetes hyperglycemia increases the proton gradient in
the mitochondrial electron transport chain (ETC) causing oxidative stress and
overproduction of superoxides [11-13]. Ultimately these pathways lead to an
increased production of vasoactive factors (VEGF, ET-1), growth factors (TGFβ1) and cytokines [11-14, 18, 19]. These factors lead to an alteration of
hemodynamic parameters such as blood flow and permeability [11-14, 18, 19]. In
addition, autocrine and paracrine properties of these factors lead to increased
production of extracellular matrix (ECM) proteins [20-22]. Imbalance in the
production and the degradation of ECM proteins like fibronectin (FN) and
collagen lead to structural alterations such as basement membrane (BM)
thickening [11-13, 20-22]. Outlined below are some specific changes seen in
diabetic complications that are of interest in this research.

1.4

Alteration of extra cellular matrix proteins
The mechanism of increased ECM protein synthesis is of great interest for

the development of therapeutic modalities, as ECM protein deposition remains
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the single most common finding in chronic diabetes [11]. Increased syntheses of
ECM proteins such as FN and collagen have been demonstrated in diabetic
angiopathy [19-22]. FN is a high molecular weight glycoprotein and a major
component of the ECM proteins. FN plays an important role in various cellular
events such as adhesion, growth, migration, differentiation and is crucial during
embryogenesis and wound healing [23]. Altered FN expression, organization and
degradation have been found to be associated with a number of pathologies
including fibrosis and cancer [23]. Our lab has shown that diabetes leads to
increased FN in all target organs of diabetic complications [11, 19-22]. We have
also shown that EDB+FN (an embryonic splice variant of FN, absent in adult
tissues) is upregulated in the ECs and retinas in diabetes [24]. EDB+FN
upregulation is dependent on ET-1 and TGF-β1 and provides outside-in
signalling, causing EC proliferation and differentiation [24]. EDB+FN gene
silencing prevented glucose-induced VEGF expression and reduced the
proliferative capacity of ECs [24].
Expression of FN in ECs exposed to high glucose is regulated by the
activation of transcription factor NF-κB [25]. NF-κB plays a pivotal role in the
regulation of several genes. In a non-stimulated cell, NF-κB dimers are
sequestered in the cytoplasm bound to a group of inhibitor proteins named IκB.
There are two classes of NF-κB (P50/52 or P65/relB c-rel) [26]. The main form of
activated NF-κB is heterodimer P50/P65 [26]. Upon stimulation, IκB is
phosphorylated by IKK and eventually degraded leaving NF-κB free to be
translocated to nucleus [26]. NF-κB in nucleus binds to the promoters of specific
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genes affecting its expression [26]. Function of transcription factor(s) such as NFκB depends on transcriptional co-activators. For example, association of NF-κB
with transcriptional co-activators p300, is essential, and without such association,
transcription factors remains silent, even following nuclear translocation [25, 26].

1.5

p300 production and histone acetylation in diabetes
EP300 or p300 is a transcriptional coactivator protein (part of the p300-

CBP coactivator family) which interacts with numerous transcription factors to
increase the expression of various target genes [27]. It has five protein
interaction domain and an intrinsic histone acetyltransferase (HAT) domain [27].
P300 regulates gene expression by relaxing the chromatin structure at the gene
promoter through their HAT activity [27]. P300 also increase gene expression by
acting as an adaptor molecule or recruiting the basal transcriptional machinery to
the promoter [27]. Mutation in p300 gene causes severe mental retardation
whereas loss of one copy of the genes prevents normal development. P300
mutation has also been found to be associated with several types of cancers
[27]. P300 has been found to be increased in response to hyperglycemia in ECs
and tissues in diabetes [28]. It regulates AP-1 and NF-kB [28]. Studies in our lab
showed increased p300 production in hyperglycemia leads to augmented histone
acetylation, activation of multiple transcription factors and increased expression
of vasoactive factors and ECM proteins in the ECs [28-30]. P300 plays a vital
role on FN, ET-1 and VEGF overexpression in the cardiac, retinal, and renal
tissue in diabetes [28-30]. DNA repair enzymes ERCC1 (DNA Excision Repair
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Protein 1) and ERCC4 (DNA Repair Endonuclease XPF) increase FN expression
in a p300-dependent manner [31]. MAPK, PKC, and Akt pathways have been
shown to mediate overexpression of p300 in response to oxidative stress [28-31].
Inhibitors of p300 have potential therapeutic value. Silencing or inhibition of p300
ameliorated the structural and functional damages of diabetic nephropathy and
cardiomyopathy [28-31]. The HAT activity of p300 is balanced by histone
deacetylases (HDACs). By deacetylating histones HDACs move chromatin to a
more repressed state controlling gene expressions [28]. Three classes of HDACs
have been identified. Class I HDACs reside in the nucleus, while class II HDACs
shuttle between the nucleus and cytoplasm. Sirtuins are class III HDACs [32-38].

1.6

SIRTUINS
Silent information regulator proteins or sirtuins (SIRTs) are class III

histone deacetylases (HDACs) and known to regulate epigenetic gene silencing
and suppress recombination of rDNA [32-38]. Initially they were identified in
yeast and were found to increase lifespan hence also known as the longevity
gene. In mammals they have a range of molecular functions and have emerged
as important proteins in aging, calorie restriction, inflammation, stress resistance,
cellular differentiation, DNA repair and metabolic regulation [32-38]. SIRTs have
a conserved 275 amino acid catalytic core domain and a unique N-terminal
and/or C-terminal sequences. SIRTs deacetylase not only histones, but also
many cellular proteins and transcription factors [38]. In addition to protein
deacetylation, studies have shown that some SIRTs also function as intracellular
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regulatory proteins with mono ADP ribosyltransferase activity [32-38]. Unlike
other known protein deacetylases, which only hydrolyze acetyl-lysine residues,
sirtuins couple lysine deacetylation to NAD hydrolysis yielding O-acetyl-ADPribose, the deacetylated substrate and NAD (itself an inhibitor of SIRT activity)
[38]. SIRTs require nicotinamide adenine dinucleotide (NAD+) for their
deacetylase or ADP-ribosyl transferase activity, linking their function strictly to
cellular energy levels [32-38]. In chronic diabetic complications, lack of available
NAD+ due to activation of polyol pathway and PARP (poly ADP ribose
polymerase), further reduces activity of SIRTs [32-38]. Furthermore glucose
induced

reduced

nicotinamidephosphoribosyl

transferase

(Nampt)

also

decreases available NAD+ and reduce SIRT activity [32-38]. In mammals, the
SIRTs represent a small gene family with seven members designated SIRT1
through SIRT7 localizing in nucleus (1, 2, 6, 7), cytoplasm (1, 2) and the
mitochondria (3, 4, 5). SIRT1, SIRT6, and SIRT7 are localized in the nucleus,
where they act to deacetylate histones thereby influencing gene expression
epigenetically [32-38]. SIRT1 further deacetylates specific transcription factors
and enzymes to influence their activities. SIRT2 was originally described as a
cytosolic molecule; however recent data show that SIRT2 is also found in the
nucleus where it functions to modulate cell cycle control. SIRT3, SIRT4, and
SIRT5 are localized in mitochondria regulating the activities of metabolic
enzymes and moderate oxidative stress in this organelle [32-38]. In general,
SIRT3–5 switch cells to favor mitochondrial oxidative metabolism, along with the
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induction of accompanying stress tolerance [32-38]. In this study we have
examined the role of SIRT1 in diabetic complications.

1.6.1 SIRT1
SIRT1 the leading member of the SIRT family resides both in the nucleus
and in the cytoplasm [39]. It has been found to regulate many central pathways
related to cellular senescence, metabolism, inflammation, insulin secretion,
tumorigenesis, cell cycle regulation, stress resistance and various diseases [3943]. SIRT1 plays a critical role in metabolic health by deacetylating many target
proteins in numerous tissues, including liver, heart, muscle, adipose tissue and
endothelium [39-43]. SIRT1 also exerts important systemic effects via the
hypothalamus [44]. In response to different environmental stimuli, SIRT1 links
the cellular metabolic status to the chromatin structure and the regulation of gene
expression, thus modulating a variety of cellular processes such as energy
metabolism and stress response [44]. Current studies have shown that SIRT1
controls both glucose and lipid metabolism in the liver, promotes mobilization of
fat and stimulates differentiation of brown and white adipose tissue, controls
pancreatic

insulin

secretion,

influences

obesity-induced

inflammation

in

macrophages and modulates the activity of circadian clock in metabolic tissues
[39-44].
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1.6.1.1 SIRT1 in pancreas
SIRT1 has been shown to be a positive regulator for pancreatic insulin
secretion, which consecutively triggers glucose uptake and utilization [45].
Increased dosage of SIRT1 in mice pancreatic beta cells improve glucose
tolerance and enhances insulin secretion [45-47]. Deletion of SIRT1 impairs
glucose-stimulated insulin secretion [45, 46]. SIRT1 has been shown to promote
insulin secretion through transcriptional repression of uncoupling protein 2
(UCP2) [46]. Activation of SIRT1 in animals protects against obesity and insulin
resistance [48]. Overexpression of SIRT1 has been found to have a protective
effect against glucose intolerance [49-52].

1.6.1.2 SIRT1 in adipose tissues
SIRT1 has been shown to repress PPARγ in white adipose tissue (WAT)
suppressing the expression of adipose tissue marker protein such as aP2 [53].
Genetic ablation of SIRT1 in adipose tissues leads to increased adiposity and
insulin resistance [54]. Treatment of mice with SIRT1 activator resveratrol has
been shown to protect against obesity and metabolic derangements [47-52]. In
addition to WAT, studies have also implicated a role of SIRT1 in the
differentiation and function of brown adipose tissue (BAT) [55]. SIRT1 promote
BAT differentiation through repression of the MyoD-mediated myogenic gene
expression and PGC-1α mediated mitochondrial gene expression [55]. SIRT1 in
propiomelanocortin (POMC) neurons selectively control perigonadal WAT to BAT
like remodeling to increase energy expenditure in female mice [56]. A recent
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study indicates that SIRT1 can also regulate the brown remodeling of WAT in
response to cold exposure by deacetylation of PPARγ [57].

1.6.1.3 SIRT1 in the hypothalamus
Recent studies have shown that both calorie restriction (CR) and fasting
enhance SIRT1 expression and activity in the hypothalamus [58]. Mice lacking
SIRT1 in the brain fail to mediate changes in pituitary signaling and physical
activity in response to CR [58, 59]. Brain-specific SIRT1 transgenic mice display
enhanced neural activity in the hypothalamus [58-60]. Inhibition of hypothalamic
SIRT1 activity has been found to increase acetylation of FOXO1 (forkhead box
protein O1), leading to increased POMC and decreased AgRP (agouti-related
peptide) expressions, thereby decreasing food intake and weight gain [61]. AgRP
specific deletion of SIRT1 alleviates the inhibitory tone on the POMC neurons
causing decreased food intake and body weight [61]. Deletion of SIRT1 in POMC
neurons in mice causes a blunted response to leptin signaling and reduced
energy expenditure leading to obesity [61]. Intra-cerebro-ventricular treatment of
resveratrol, a known SIRT1 activator normalizes hyperglycemia and improves
hyperinsulinemia in obese mice with diabetes [62].

1.6.1.4 SIRT1 in hepatic glucose and lipid metabolism
SIRT1 is an important regulator of hepatic glucose metabolism [63].
Hepatic SIRT1 is a key modulator of gluconeogenesis in response to fasting [64].
Fasting increases SIRT1-mediated deacetylation and activation of PGC-1α,
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resulting in increased fatty acid oxidation and improved glucose homeostasis
[63]. SIRT1 also plays an important role in hepatic fatty acid metabolism [65].
Adenoviral knockdown of SIRT1 reduces expression of fatty acid β-oxidation
genes in the liver [65]. Specific deletion of the exon 4 of the mouse hepatic
SIRT1 gene, results in an inactive SIRT1 protein which impairs fatty acid βoxidation through the PPARα/PGC-1α pathway [66, 67]. This increases the
susceptibility of mice to dyslipidemia, hepatic steatosis, inflammation, and
endoplasmic reticulum (ER) stress [68]. Overexpression of SIRT1 in mice liver
attenuates hepatic steatosis and ER stress restoring glucose homeostasis [68].
SIRT1 also regulates hepatic cholesterol and bile acid through direct modulation
of the liver X receptors (LXRs) and farnesoid X receptor (FXR) [69-71]. Systemic
deletion of SIRT1 in mice results in decreased serum high density lipoprotein
(HDL) levels [72]. SIRT1 also regulate hepatic lipid metabolism through
deacetylation of SREBPs (sterol regulatory element binding proteins), critical
regulators of lipid and cholesterol genesis [73].

1.6.1.5 SIRT1 in inflammation
Researchers have identified SIRT1 as an important repressor of
inflammation in multiple tissues and cells including the macrophages [74-76]. In
mice, overexpression of SIRT1 causes suppression of the inflammatory response
and insufficiency of SIRT1 induces systemic inflammation [77]. Deletion of SIRT1
in hepatocytes results in increased local inflammation [78]. Several recent
studies indicate that SIRT1 suppress the activity of NF-κB, the central regulator
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of cellular inflammatory response [79, 80]. SIRT1 deacetylates the RelA/p65
subunit of NF-κB, leading to decreases in the NF-kB transcriptional activity thus
reducing expression of pro-inflammatory cytokines [80]. Overexpression of
SIRT1 in mice leads to reduced NF-κB activity, while knockdown of SIRT1 in the
mouse macrophages increases LPS-stimulated TNFα (tumor necrosis factor α)
secretion [79, 80]. Moreover, smoking decreases SIRT1 levels in human
macrophages leading to increased activation of NF-κB mediated proinflammatory response by these cells [80]. In a macrophage-specific knockout
mouse SIRT1 attenuates NF-κB mediated gene transcription thus predisposing
mice to the development of insulin resistance and metabolic disorders [80]. The
activity and expression of SIRT1 are also under control of systemic inflammation
[79]. It has been shown that interferon gamma (IFNγ), represses the transcription
of SIRT1, thereby disrupting metabolism and energy expenditure [81].

1.6.1.6 SIRT1 and circadian rhythm
Circadian rhythm is the biological 24 hour oscillation present in all living
beings and work in part through chromatin modification and epigenetic control of
gene expression [82]. Studies have shown that SIRT1 interacts with CLOCKBMAL1 (circadian locomotor output cycles kaput-aryl hydrocarbon receptor
nuclear translocator-like, dimer transcription factor) to directly regulate the
amplitude and duration of circadian clock controlled gene expression through
deacetylation of PER2 (perdio carcadian protein homolog 2) and/or BMAL1 [83].
More over circadian regulation of SIRT1 activity is regulated by the cellular NAD
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levels [84]. Phosphorylation of SIRT1 by DYRK1A (dual specificity tyrosinephosphorylation-regulated kinase 1A), an essential clock component activates its
NAD dependent deacetylases activity in response to various environmental
stresses [85-87]. These studies show a feedback loop involving CLOCK-BMAL1,
Nampt, NAD and SIRT1, providing an important connection between
physiological rhythm and cellular metabolism [85-87].

1.6.1.7 SIRT1 regulates insulin sensitivity
SIRT1 has been shown to directly regulate pancreatic insulin secretion
thus improving systemic insulin sensitivity [45]. In skeletal muscle SIRT1 has
been shown to stimulate mitochondrial fatty acid oxidation through PGC-1α
thereby promoting insulin sensitivity [88, 89]. Moreover, SIRT1 improves
systemic insulin sensitivity through interaction with AMP-activated protein kinase
(AMPK) increasing fatty acid oxidation and mitochondrial biogenesis [90]. SIRT1
directly regulates the secretion of adiponectin from adipocytes through
deacetylation of FOXO1, improving insulin sensitivity in the liver and muscle
tissues [91-94]. SIRT1 also represses the expression of PTP1B (protein-tyrosine
phosphatase 1B) which is a negative regulator of insulin signaling, thereby
improving insulin sensitivity under insulin-resistant conditions [95]. SIRT1 interact
with insulin receptor substrates, IRS-1 and IRS-2 modulating insulin signaling
[96]. Genetic deletion of SIRT1 in adipose tissues, myeloid cells and liver or
systemic loss of a single copy of the SIRT1 gene has been found to cause the
development of insulin resistance and signs of metabolic syndrome [97].
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Activation of SIRT1 by its activators such as the resveratrol and SRT1720 in
animals protected against high-fat-induced obesity and insulin resistance [49-51].

1.6.1.8 SIRT1 in endothelial cells and atherosclerosis
SIRT1 is prominently expressed in ECs of growing blood vessel sprouts
[98]. Loss of endothelial SIRT1 activity impaired the ability of ECs to form new
vessels in response to ischemic stress [98]. Inactivations of SIRT1 impaired
endothelial migration and sprout elongation and caused defects in vessel
navigation, whereas overexpression of SIRT1 augmented such process [98]. In
the vasculature of rodent models SIRT1 mediates vasodilatation via eNOSderived nitric oxide (NO) and scavenging reactive oxygen species (ROS) [99]. In
the ECs SIRT1 plays an anti-inflammatory function by downregulating the
expression of various pro-inflammatory genes (P-Selectin, ICAM-1 and VCAM-1)
through the NF-κB signaling pathway [100]. SIR T1 in macrophages suppresses
the expression of Lox-1 which is a scavenger receptor for oxidized low-density
lipoproteins

(oxLDL),

preventing

macrophage

foam

cell

formation

in

atherosclerosis [101]. Also, SIRT1 has been shown to regulate the activity of
Liver X-receptor (LXR), promoting ABCA1-driven reverse cholesterol transport in
plaque

macrophages

[101].

SIRT1

exerts

antithrombotic

properties

by

suppresseing the expression of endothelial tissue factor (coagulation factor III)
[102, 103]. SIRT1 deacetylase p53 in ECs preventing its activation and causing
protection

against

vascular

senescence

in

hyperglycemia

[104,

105].

Overexpression of SIRT1 diminishes atherogenesis in mice and improves
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vascular function [105]. Deletion of one SIRT1 allele increased atherosclerosis in
hypercholesterolemic mice [101].

1.7

FOXO1
Some of the SIRTs activities are carried out through deacetylation of the

FOXOs, i.e, forkhead family ‘O’ group of transcription factors [106]. Among the
FOXO family, FOXO1 is best characterized and plays important roles in oxidative
stress resistance, cell survival and cell death [107]. FOXO1 has a highly
conserved DNA binding domain subjected to posttranslational modifications such
as acetylation, phosphorylation and ubiquitination [108]. Such modifications can
either increase or decrease the transcriptional activity of FOXO1 [108]. FOXO1
acetylation by HAT such as p300 causes attenuation of its DNA binding ability
and facilitates its phosphorylation by Akt, which leads to its export from the
nucleus; whereas deacetylation increases FOXO1’s nuclear retention and
transcriptional activity [106-108]. During oxidative stress FOXO1 is known to
increase the expression of antioxidant genes (manganese superoxide dismutase,
catalase) and thus promotes the scavenging of reactive oxygen species
preventing DNA damages [109-112]. FOXO1 has important roles in systemic
homeostasis. In mice, loss of FOXO1 is embryonically lethal [113]. FOXO1 also
plays a role in regulating cardiac glucose and fatty acid (FA) metabolism [114].
FOXO1

upregulates

gluconeogenesis

by

increasing

hepatic

glucose-6-

phosphatase and phosphoenolpyruvate carboxykinase [115]. In skeletal muscle
and in HepG2 cells, FOXO1 increase pyruvate dehydrogenase kinase (PDK4)
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expression thereby regulating glucose oxidation [116]. In chronic hyperglycemia,
advanced glycated end products and their receptor activation cause modification
of FOXO1 which enhance its transcriptional function independent of the
phosphorylation state [117]. In diabetes, there is a decreased check on FOXO1
activity

by

the

insulin

signaling

pathway

[118].

Under

conditions

of

hypoxia/ischemia, transcription factors like hypoxia inducible factor (HIF-1α) are
shown to interact with FOXO1 and enhance their transcriptional function [119]. In
the liver, following FOX1 activation, important enzymes of gluconeogenesis like
glucose-6-phosphatase, fructose-1,6-biphosphatase and phosphoenolpyruvate
carboxykinase are increased [120]. FoxO1 is also known to enhance lipogenesis
and lipid induced steatosis in liver [120]. In beta cells FOXO1 inhibit pancreatic
and duodenal homeobox factor 1 (Pdx1) causing damage of beta cell function
[121]. Due to their ability to promote cell cycle arrest by activation of p27kip1 (a
G1 cyclin inhibitor) and c-myc (transcription factor), FOXO1 also have a tumor
suppressive role [122]. Through the activation of pro-apoptotic proteins like Bim
and caspases, they are known to increase tumor cell death [122]. Another
important role of FOXO1 in inflammation and sepsis has been explored through
their ability to co-ordinate with TLR4 (Toll-like receptor 4) and NF-κB [123].

1.8

SIRT1 regulation by miRNAs
miRNAs are small, non-protein coding RNAs, approximately 19-24

nucleotides in length and highly conserved among species [124]. They regulate
gene expression at the post transcriptional level through interaction with their
target mRNA 3' untranslated region (UTR) [125]. miRNAs have significant effects
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on the regulation of gene expression. The transcription of the miRNA occurs
through RNA polymerase II [124-126]. The processing to precursor miRNAs
(hairpin shaped, 70-100 nucleotides) in the nucleus is mediated by RNAse III,
Dorsha and DGCR8. Following synthesis, they are exported to the cytoplasm by
exportin 5 [126]. In the cytoplasm, they are further processed by Dicer into the
functionally active mature miRNA. miRNA binds to the specific mRNA targets
and causing degradation of specific mRNA or translational repression [124-126].
Several investigators have demonstrated importance of miRNA in diverse cellular
processes [124-131]. miRNAs also play important roles in controlling histone
modification. A significant number of miRNA coding regions are located in the
intron of the protein coding gene and are usually co-regulated with their host
genes [124-126].
Epigenetic mechanisms play a fundamental role in the regulation of
miRNAs [124-131]. In mammals, it is estimated that over one third of genes are
regulated by miRNAs and on average one miRNA may regulate 100-200 different
target genes, and a single gene may have several targets sites for various
miRNA [124-126]. miRNAs are important players in a variety of cellular
processes [128-137]. We have recently identified alterations of several miRNAs
in diabetes [133-137].
Sixteen miRNAs have been found to regulate SIRT1 [138]. These miRNAs
regulate SIRT1 in brain, liver, pancreas, cardiac metabolism and tumorigenesis
in various disease and normal conditions [138]. With respect to this project, we
have identified by array studies significant upregulation of miRNA195 (a SIRT1
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targeting miRNA) in the ECs exposed to glucose and in the retinal tissue in
diabetes.

1.9

Similarities of diabetic complications with aging
A large number of structural and functional changes seen in diabetic

complications are also found in normal cellular aging [139-158]. Cellular aging
process or senescence is a phenomenon where cells demonstrate a reduced
ability to multiply. It is characterized by reduced ability to respond to stress,
increased susceptibility to diseases or infection, increased secretion of proinflammatory cytokines, chemokines, growth factors, ECM proteins and
increased homeostatic imbalance [139-158]. The biological basis of aging is still
unknown however increased oxidative stress and DNA damage are known to
induce senescence in cells [139-158].
It is proposed that aging and longevity are determined by a complex
mixture of environmental and genetic factors [139-158]. Researchers have
demonstrated that selected alterations in specific genes can extend lifespan in
model organisms and laboratory settings [49-51, 159, 160]. Increased DNA
repair and telomerase activity, reduced oxidative damage and cell apoptosis can
extend life span [139-158]. DNA damage is thought to be a common cause of
aging [142, 150-158]. DNA damage caused by extrinsic factors such as,
radiation, chemical or viral infection can prevent cell division or cause apoptosis
in cells [142, 150-158]. It can often affect the stem cell pools hampering
regeneration. However intrinsic causes such as ROS/RNS (reactive oxygen
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species/reactive nitrogen species) are considered as one of the major drivers of
DNA damage and aging [139-158].
Three metabolic pathways have been identified which influence the rate of
aging: caloric restriction, the activity levels of the electron transport chain in the
mitochondria and the insulin/IGF-1-like signaling pathway [161]. It may be
possible that these three pathways affect aging separately as simultaneously
targeting those leads to additive increases in lifespan [161]. The SIRT family of
genes has been shown to have a significant effect on the lifespan of several
species [32-34, 40]. In addition, diet has been shown to substantially affect
lifespan in many animals including prevention or delay of many age-related
diseases. In several model species caloric restriction has been found to lead to
longer lifespans mediated by the nutrient-sensing function of the mTOR
(mammalian target of rapamycin) pathway [140, 159-161]. This is thought to
prevent spikes of glucose concentration in the blood, leading to improved insulin
signaling [161]. Evidence in both animals and humans suggests that resveratrol,
a known SIRT activator may be a caloric restriction mimetic [49-51, 161]. As
more genetic connections to aging are being discovered, it is increasingly being
considered similar to other genetically influenced conditions and potentially
treatable. Similar to aging in diabetes, glucose induced oxidative damage is a
key mediator of cellular damage. Such oxidative damage causes activation of
several metabolic pathways ultimately converging on the nucleus. We and others
have shown oxidative stress induced DNA damage in diabetes [11-13].
Ultimately such process causes aberrant expressions of cytokines, growth
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factors, ECM proteins and structurally manifesting as changes such as cell loss,
vascular sclerosis etc [11-13, 17-21, 24, 25, 28-31]. Hence tissue damage in both
aging and diabetes may in part be mediated by similar mechanisms.

1.10 Rationale
As discussed above, changes in ECs and organs in diabetes such as
increased oxidative stress, increased AGE, DNA damage, ECM protein
production, cognitive decline, atherosclerosis, small vessel sclerosis are also
observed in normal aging. Hence it is possible that high glucose in diabetes
actually accelerates the aging process in cells and tissues. The mechanism of
such process was investigated in this research.

1.11 Hypothesis
Diabetes, through oxidative damage, causes alteration of specific nuclear
enzymes leading to an accelerated aging process. Such changes lead to
alteration of vasoactive molecules and ECM proteins and causes development of
chronic complications.

1.12 Specific aims
1. Aim1-to investigate accelerated aging in endothelial cells and in tissues in
response to hyperglycemia and examine the role of SIRTs in such process
2. Aim 2- to investigate SIRT1 regulation by microRNA 195 in diabetic
animals

23

3. Aim 3-to investigate the effect of SIRT1 overexpression in the organ
damage in diabetic animals
Aim 1 was investigated in chapter 2. Aim 2 was investigated in chapter 3. Aim 3
was investigated in chapter 4.
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2

High glucose induced alteration of SIRTS in
endothelial cells causes rapid aging in a p300 and
FOXO regulated pathwaya

Rokhsana Mortuza, Sali Chen, Biao Feng, Subhrojit Sen and Subrata
Chakrabarti. Department of Pathology, Schulich School of Medicine & Dentistry,
Western University, London ON Canada.
In this study our aim was to investigate accelerated aging in endothelial
cells and in tissues in response to hyperglycemia and examine the role of SIRTs
in such process. We examined 3 different ECs of various origins as well as
kidney and retinal tissues of type 1 diabetic mice for this investigation. We also
looked at the possible mechanism behind such glucose-induced rapid aging
process.
aA
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2.1

Introduction
Diabetes and its complications account for significant morbidity and

mortality throughout the world [1-3]. The major factor in the development of
chronic diabetic complications is vascular EC dysfunction [4]. The prevailing
mechanism leading to EC dysfunction is an increase in reactive oxygen species
(ROS) formation [5]. In response to high ambient glucose levels and subsequent
oxidative stress, ECs elaborate large amount of vasoactive factors, growth
factors and cytokines [6, 7]. Such factors lead to increased production of
extracellular matrix (ECM) proteins

causing structural alterations

[6-8].

Interestingly, several such changes seen at the cellular and tissue level in
diabetes are similar to the changes seen in normal aging process [9-13].
Oxidative stress causes DNA damage and alters transcriptional machinery
both in aging and in diabetes [4, 6, 14, 15]. We have previously shown that
glucose induced oxidative stress causes histone acetylation by p300, which
regulates several transcripts in diabetes [6, 16]. p300, a transcriptional
coactivator with an intrinsic histone acetyltransferase (HAT) activity, regulates
numerous transcription factors [6, 16, 17]. Acetylation by p300 and other HATs
are balanced by histone deacetylases (HDACs).
Silent information regulator 2 proteins or sirtuins (SIRTs) belong to Class
III HDACs and regulates epigenetic gene silencing and suppress recombination
of rDNA [18-20]. In mammals, SIRTs have a range of molecular functions and
have emerged as important proteins in aging and metabolic regulations [18, 21].

40

SIRTs represent a small gene family with seven members designated as SIRT17, known to be modulated by oxidative stress [22].
Some of the SIRTs activity is carried out through deacetylation of the
FOXOs, forkhead family ‘O’ group of transcription factors [23-25]. Among the
FOXO family, FOXO1 is best characterized and plays important roles in cell
survival, oxidative stress resistance and cell death [26-29]. FOXO1 has a highly
conserved DNA binding domain subjected to posttranslational modifications such
as phosphorylation, acetylation and ubiquitination. These modifications can either
increase or decrease the transcriptional activity of FOXO1 [17]. FOXO1
acetylation by HAT such as p300, leads to attenuation of its DNA binding ability
and facilitates its phosphorylation by Akt, leading to its export from the nucleus;
whereas deacetylation increases FOXO1’s transcriptional activity [17, 24].
The purpose of this study was to investigate whether high glucose causes
accelerated aging process in ECs through alteration of SIRTs. We further
investigated whether the effects of SIRTs are mediated through FOXO1 and if
such process is regulated by histone acetylase p300. We carried out these
studies in various ECs as well as in the diabetic animals.

2.2

Materials and methods

2.2.1 Cell culture
Dermal-derived human microvascular EC (HMEC) was obtained from
Lonza, Inc. (Walkersville, MD) and grown in EC basal medium 2 (EBM-2,
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complete). Human umbilical vein ECs (HUVECs) were obtained from Lonza and
cultured in EC growth medium (EBM complete, Walkersville, MD). Bovine retinal
microvascular ECs (BRECs) were obtained from VEC Technologies (Rensselaer,
NY) and grown in a defined EC growth medium (MCDB-131 complete). We have
previously described the culture conditions of these three cells [30, 31]. No
insulin was present in any media.
For the long term continuous exposure to glucose, ECs were cultured in
12 well plates (Corning, Acton, MA) and treated with 5mM glucose (NG) or 25mM
glucose (HG, D-glucose) or osmotic control (OSM, 25 mM L-glucose). Upon
confluence cells were propagated & maintained in the same treatment condition
until they stopped proliferating completely. During each passage subculture cells
from each treatment group were stained for SA β-gal and collected for RNA
analysis. Cell lysates were collected with RIPA (Millipore, Billerica, MA) buffer
with protease inhibitor (Roche, Laval, Canada) for ROS and MnSOD analysis.
Total protein concentrations were measured by BCA protein assay kit (Pierce,
Rockford, IL). Cells were monitored daily and images taken for morpholocigal
and growth analysis. All experiments were conducted with 6-10 biological
replicates.
To test the effect of SIRT1 activation on accelerated aging in diabetes,
cells were treated with 10 µM resveratrol (Sigma, Oakville, ON, Canada)
dissolved in ethanol or 25 µM BML278 (Enzo, Farmingdale, NY) in DMSO for 72
hr in HG following subculture in HMEC P1 (P1 = passage 1). To investigate the
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effect of FOXO1 inhibition, cells were treated with 0.1 µM FOXO1 inhibitor
AS1842856 (Millipore, Billerica, MA) in DMSO similarly.

2.2.2 Animal experiments
Male C57BL/6 mice (20-25g), were obtained (Charles River, Wilmington,
MA) and diabetes was induced by a single intraperitoneal injection of
streptozotocin (STZ) (65 mg/kg, in citrate buffer, pH 5.6). Age- and sex-matched
mice were used as controls and given equal volumes of citrate buffer [32]. db/db
(Leprdb, DBA/J) mice (8 weeks, Jackson Laboratory, CA) were used as type 2
model of Diabetes [32]. The animals were monitored daily as described by us
previously [32]. The animals were killed at 2 & 4 months following the
development of diabetes (n = 10/group). Retinal and renal cortical tissues were
dissected out and snap frozen in liquid nitrogen. All tissues were stored at −80°C
until further analysis. Urinary albumin (Exocell, Philadelphia, PA) and serum
creatinine (Arbor assays, Ann Arbor, MI) were measured as per the instructions.

2.2.3 Ethics statement
Animal experiments were performed in accordance with regulations
specified by the Canadian Council of Animal Care. The investigation was in
compliance with the Guide for the Care and Use of Laboratory Animals (NIH
publ. no. 85-23, revised 1996). All protocols were approved by the University of
Western Ontario Animal Care and Veterinary Service.
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2.2.4 SA β-gal staining of cells and frozen tissue sections
Cells from each passage or tissue slides were fixed and stained with SA
β-gal staining according to the manufacturer’s instructions (abcam, Cambridge,
MA). Tissue slides were counterstained with H&E for orientation purpose.

2.2.5 Phase contrast microscopy and morphometrical analysis
Images of SA β-gal stained cells were photographed with phase contrast
inverted microscope (Meiji Techno, TC5400, Santa Clara, CA) with 20X objective
and SPOT Basic software. Morphometrical analysis of the images was done by
ImageJ software (NIH, Bethesda, MD). Images (10 per sample) of the tissue
slides were recorded by an Olympus BX51 microscope (Olympus, Center Valley,
PA) with Northern Eclipse software (Empix Inc, Cheektowaga, NY).

2.2.6 mRNA extraction and cDNA synthesis
RNA extraction and cDNA synthesis from cells and tissues samples has
been described by us previously [30]. RNA concentration was assessed on a
spectrophotometer (Pharmacia Gene Quant, GE, Mississauga, ON, Canada).
First-strand cDNA was made by using High Capacity cDNA Reverse
Transcription kit (Applied Biosystems, Carlsbad, CA, USA) as per the
manufacturer instruction.
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2.2.7 mRNA analysis with quantitative Real Time RT-PCR
Real-time RT-PCR was performed by LightCycler™ (Roche Diagnostics,
Laval, Canada) to quantify the mRNA expression of SIRT1, SIRT2, SIRT3,
SIRT4, SIRT5, SIRT6, SIRT7, TERT (telomerase reverse transcriptase)

and

p300 using the Qiagen One Step RT-PCR kit (SYBR Green I detection platform).
All primers were either ordered or custom made from Sigma (Table 2.1). The
data were normalized to housekeeping gene β-actin/18s mRNA to account for
differences in reverse transcription efficiencies and the amount of template in the
reaction mixtures. The details of the method have been described by us
previously [30].
Table 2.1 The primers sequences for Real Time RT-PCR.

Name of Primer

Sequence (5’ to 3’)

TERT

CGTGGTTTCTGTGTGGTGTC
CCTTGTCGCCTGAGGAGTAG
AAGAGCGTGCCCTACTTCAA
CTGTTGTTGTCCATGGATGC
CATGAGCTGCAGTGACTGGT
GAGCTTGCCGTTCAACTAGG
CAGCAAGTCCTCCTCTGGAC
CCAGCCTACGAAGTTTCTCG
AGGATGTCGGTGAATTACGC
AAAGGTGGTGTCGAACTTGG
GACTTTCGCTCTCCATCCAC
GGAGTAGCCCCTTGTCCTTC
CCAGATTGTCCCAAGTCGAT
CTGAAGGTCGGAACACCACT
AGGGAGAAGCGTTAGTGCTG
GGAACGCAGGAGGTACAGAC
GCAGATTAGTAGGCGGCTTG
TCTGGCATGTCCCACTATCA
GGGACTAACCAATGGTGGTG

FOXO1
SIRT3
SIRT4
SIRT6
SIRT2
SIRT5
SIRT7
SIRT1
P300

45

ATTGGGAGAAGTCAAGCCTG

2.2.8 Nuclear fraction isolation
Nuclear fractions were isolated from ECs and tissues as per the kit
instruction (Active Motif, Carlsbad, CA). Protein concentrations in the samples
were measured by BCA protein assay (Pierce, Rockford, IL).

2.2.9 FOXO1 DNA binding activity measurement
FOXO1 DNA binding ELISA was conducted on the collected nuclear
fraction as per the manufacturer’s instruction (Active Motif, Carlsbad, CA). The
plates were read at 450 nm using a plate reader (Multiskan, Thermo Fisher,
Canada).

2.2.10 ROS, MnSOD and LDH analysis
Total ROS level in the EC lysates were measured as per the manufacturer
instructions using a commercially available kit (Cell Biolabs Inc., San Diego, CA).
The plates were read with a fluorescent plate reader (Biotek, Winooski, VT) at
excitation 480 nm and emission 530 nm. MnSOD ELISA was done on cell and
tissue lysates as per the manufacturer instruction (abcam, Cambridge, MA). The
plates were read at 450 nm using a plate reader (Multiskan, Thermo Fisher,
Canada). Total protein concentrations were measured by BCA protein assay kit
(Pierce, Rockford, IL). Quantification of intracellular lactate dehydrogenase (LDH)
in the cell lysates was used as an additional measure of cell growth. The assay
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was conducted as per the manufacturer instruction (Caymen Chemical
Company, Ann Arbor, MI).

2.2.11 Telomerase activity
Telomerase activities of the samples were measured using a commercially
available kit following instructions provided by the manufacturer (Allied Biotech
Inc., Vallejo, CA).

2.2.12 Western blot
200µg of protein was used for the western blot analysis according to the
standard protocol established at our lab [6] using p300, Ac-FOXO1 & β-actin
antibody (Santa Cruz Biotechnology, Santa Cruz, CA).

2.2.13 SIRT1 enzyme activity analysis
Enzyme assay for SIRT1 activity was performed as per the manufacturer
instructions (Sigma, Oakville, CA). The plates were read with a fluorescent
spectrophotometer (Biotek, Winooski, VT) at excitation 340 nm and emission 430
nm.

2.2.14 SIRT1 gene silencing
To silence SIRT1, transfection of small interfering RNA (siRNA) was
performed using N-TER nanoparticle siRNA transfection system (Sigma,
Oakville, Canada) according to the manufacture’s protocol. SIRT1 siRNA1 was
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purchased from Dharmacon Inc. (Lafayette, CO) and SIRT1 siRNA2 was
purchased from Santa Cruz Biotecnology (Santa Cruz, CA). Cells were incubated
with or without glucose after transfection for 24 hr and sample collected for
mRNA analysis. To test the effect of SIRT1 siRNA on resveratrol, the siRNA was
added 48 hr post treatment with resveratrol in the cultured cells and samples
collected 24 hr post transfection. Transfection efficiency was assessed by realtime RT-PCR.

2.2.15 P300 gene silencing
To silence the p300 expression in ECs, p300 siRNA1 (Silencer, Ambion,
Austin, TX) and p300 siRNA2 (Santa Cruz Biotechnology, Santa Cruz, CA) was
used with siPORT Lipid transfection reagent (Ambion, Carlbad, CA). The details
of the transfection protocol has been described by us previously [6,16]. siRNA
transfection efficiency was indirectly assessed by measuring p300 mRNA
expression by real-time RT-PCR.

2.2.16 Statistical analysis
Data are expressed as mean ± SEM (n ≥ 6), normalized to controls. The
statistical significance of the results was analyzed by one way or two way
ANOVA followed by Tukey’s HSD post hoc correction and the two tailed
Student’s t-test as appropriate (PASW Statistics 18, IBM, Canada). P value <
0.05 was considered statistically significant.
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2.3

Results

2.3.1 High glucose accelerates aging process in the ECs.
Suspecting that hyperglycemia accelerates aging, we first investigated
whether glucose causes rapid aging process in the ECs as they are the primary
target of diabetic vascular complications. We examined three different ECs of
various origins, at various passages following treatment with high glucose and
used morphological alteration & senescence associated β-gal positivity as two
biomarkers of aging.
We found aging changes in HMEC starts as early as passage 1, as seen
from positive β-gal staining in HG treated cells compared to NG treated cells
where it appeared in passage 4. By passage 5, all cells in HG showed such
changes, whereas in NG it was present in only 1.5% cells (Figure 2.1A and B).
Additionally, cell growth was slower in HG treated groups compared to the NG
treated cells. By passage 5, the HG treated cells stopped proliferating
completely, whereas the cells in NG continued to do so (Figure 2.1D-F). The
morphology of the cells also changed as they got older. The older cells became
larger and irregular in shape compared to the smaller spindle shaped young
cells. This process was exaggerated in HG. The average cell size in HG was
significantly larger than the controls (Figure 2.1C).
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Figure 2.1 Aging signs in microvascular endothelial cells (HMEC) with HG start
as early as passage 1. (A) SA-βgal staining showed increased β-gal positivity or
senescent cells with HG treatment compared to the NG treated cells, with the
increasing passage number. Arrow indicates β-gal positive (blue) cells. [Scale
bar represent 100µm for all micrographs]. (B) Quantification of β-gal positivity
(n=10 image per sample). Signs of cellular aging started to appear from passage
1 in HG. (C) Morphometric cell area analysis showed significant increase in cell
size with HG treatment. Cell growth was slow with HG treatment compared to
controls as seen from (D) days needed to be confluent in HG (90%, at which
stage cells were subcultured to next passage), (E) cell count in HG (attached
cells per microscopic field at 20X objective, n = 10 image) and (F) reduced
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intracellular LDH activity in HG. (NG = normal glucose, 5 mM; HG = high
glucose, 25 mM D-glucose; OSM = osmotic control, 25 Mm L-glucose; P =
passage number). [*p<0.05 compared to NGP1; ǂp<0.05, ǂǂp<0.01 compared to
respective NG passages for HG cultured cells].
We then examined retinal endothelial cells, a major target in diabetic
retinopathy. We found similar changes. In HG, BREC showed increased β-gal
positivity and slower growth (Figure 2.2A and D-F). Similar to HMEC, such aging
started as early as passage 1 in HG treated cells whereas with NG it appeared at
passage 4. At passage 8 complete growth arrest and 100% β-gal positivity was
seen in HG compared to 35% positivity in NG treated cells (Figure 2.2B).
Furthermore, morphologically such aging changes were associated with a large
and irregular appearance (Figure 2.2C).
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Figure 2.2 Accelerated aging and associated changes in retinal endothelial cells
(BREC) with increasing passages with HG treatment. (A) SA-βgal staining
showing increased β-gal positivity (A) with HG treatment. Arrow indicates β-gal
positive cells. [Scale bar represent 100µm for all micrographs]. (B) Quantification
of β-gal positivity. Aging signs appeared at passage 1 with HG. (C) Morphometric
cell area analysis showed significant increase in cell size with HG treatment. Cell
growth was slow with HG treatment compared to controls as seen from (D) days
needed to be confluent (90%, at which stage cells were subcultured to next
passage), (E) cell count (attached cells per microscopic field at 20X objective, n =
10 image) and (F) reduced intracellular LDH activity. (NG = normal glucose, 5
mM; HG = high glucose, 25 mM D-glucose; OSM = osmotic control, 25 mM L-
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glucose; P = passage number). [*p<0.05, **p<0.01 compared to NGP1; ǂp<0.05,
ǂǂp<0.01 compared to respective NG passages for HG cultured cells].
Interestingly, although HUVECs showed similar changes, such process
was delayed. HUVECs were a better survivor in HG environment. They were
able to grow up to 11 passages in HG (Figure 2.3A). They showed signs of aging
with HG at passage 4 and with NG at passage 7. β-gal positivity reached 100%
at passage 11 in HG compared to 60% in NG at the same passage (Figure
2.3B). In addition, similar to other ECs, aging was associated with large and
irregular shape of these cells along with slow growth, (Figure 2.3C and D-F).
Such changes were not seen with 25mM L-glucose (osmotic control) in any of
the cell types (Figure 2.1, Figure 2.2 and Figure 2.3).

53

Figure 2.3 Accelerated aging in large vessel endothelial cells (HUVEC) with HG
is delayed. (A) SA-βgal staining showed increased β-gal positivity (blue cells as
indicated by arrow) with HG treatment compared to NG and osmotic control
groups. Aging signs appeared later with HG in HUVEC. [Scale bar represent
100µm for all micrographs]. (B) Quantification of β-gal positivity shows increased
percentage of aged cells in HG treated group. (C) Morphometric cell area
analysis showed significant increase in cell size with HG treatment. Cell growth
was slow with HG treatment compared to controls as seen from (D) days needed
to be confluent in HG (90%, at which stage cells were subcultured to next
passage), (E) cell count in HG (attached cells per microscopic field at 20X
objective, n = 10 image) and reduced (F) intracellular LDH activity in HG. (NG =
normal glucose, 5 mM; HG = high glucose, 25 mM D-glucose; OSM = osmotic
control, 25 mM L-glucose; P = passage number). [*p<0.05, **p<0.01 compared to
NGP1; ǂp<0.05, ǂǂp<0.01 compared to respective NG passages for HG cultured
cells].
As reduction of TERT has been found in many models of cellular aging,
we investigated possible alteration in TERT mRNA expression. We investigated
them at an early stage, (P1) and at the end passage (P5 in HMEC, P8 in BREC
and P11 in HUVEC). We noticed TERT mRNA was significantly reduced in all
ECs with HG treatment along with accelerated aging (Figure 2.4A).
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Figure 2.4 Increased oxidative stress and reduced TERT mRNA expression
observed in endothelial cells with HG. (A) HMEC, BREC & HUVEC showed
reduction of TERT (telomerase reverse transcriptase) mRNA in HG treated cells.
mRNA levels are expressed as a ratio to 18s and normalized to NG P1. (B) Total
ROS levels in HMEC, BREC & HUVEC showed significant increase with HG and
aging. MnSOD levels in all cells at end passages (P5 in HMEC, P8 in BREC and
P11 in HUVEC) showed significant reduction with HG treatment (C). (NG = 5
mM; HG = 25 mM glucose, P1 = passage 1). Data normalized to NG (P1)
treatments of the respective ECs. [*p <0.05 compared to NGP1; ǂp<0.05
compared to NGP5 for HMEC, NGP8 for BREC and NGP11 for HUVEC].
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In order to see whether such accelerated aging is associated with
oxidative stress, we measured total ROS level in the cell lysate from early and
late passages between the treatment groups. As anticipated, we found with HG
the ECs produced more ROS than with NG, depicting higher level of oxidative
stress in hyperglycaemia, which augmented with the increased passage number
or aging (Figure 2.4B).
Disruption of the scavenging of ROS in the mitochondria in aging is well
known [33]. Manganese superoxide dismutase (MnSOD) is the primary
mitochondrial ROS scavenging enzyme. It converts superoxide to hydrogen
peroxide which is eventually converted to water by catalases and other
peroxidases [29, 33, 34]. Our investigation of MnSOD in the final passages of the
ECs showed a significant reduction of the enzyme in the aged cells (Figure
2.4C).

2.3.2 High glucose exaggerates down regulation of SIRTs in aging.
We then examined whether above changes are associated with alteration
of SIRTs. We found mRNA expressions of all SIRT (1-7) genes were reduced
with increasing passages, in all ECs (Figure 2.5A, Figure 2.6A & Figure 2.7A).
Such reduction was faster and exaggerated in HG treated groups. There were
25-50% reductions in SIRT mRNA expressions with HG from as early as
passage 1 in HMECs, which increased to 50% at passage 5 (Figure 2.5A).
Similar reductions were observed in the BRECs (Figure 2.6A). HUVECs
however, exhibited smaller reduction (15-30%) in earlier passages (Figure 2.7A).
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Nonetheless by passage 11, mRNA levels in HG in HUVEC were reduced to
almost half of NG treated cells (Figure 2.7A). Reduction in SIRT1 enzyme
activities found in the ECs in final passages with HG treatment, were in keeping
with the reduced mRNA levels (Figure 2.5B, Figure 2.6B & Figure 2.7B). As
SIRT1 is one of the most important isoforms of the SIRT family which is
associated with aging [5, 18, 24, 34], we focused on SIRT1 for the subsequent
experiments. We carried out the following experiments in HMECs, as they are
the major target of diabetic complications.

Figure 2.5 SIRT (1-7) mRNA reduction in HG in microvascular endothelial cells
(HMECs) parallels the accelerated aging. (A) Quantitative Real Time RT-PCR of
SIRTs in HMEC showed significant reduction in the SIRT mRNA levels in HG
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treated cells. mRNA levels are expressed as a ratio to β-actin normalized to
baseline controls, NG P0 ( P0 = before start of treatment). [*p<0.05 compared to
NGP0; ǂp<0.05 compared to respective NG passages for HG cultured cells]. (B)
SIRT1 enzyme activity was reduced in HG in these endothelial cells (P5, data
normalized to NG). (NG = 5 mM; HG = 25 mM glucose; P = passage number).
[*p<0.05 compared to NGP5].

Figure 2.6 SIRT 1-7 mRNA analysis with Quantitative Real Time RT-PCR at
various passages in BREC showed significant reduction in HG treated cells. (A)
SIRT (1-7) mRNA expressions in BREC with increasing passages. mRNA levels
are expressed as a ratio to β-actin and normalized to baseline controls, NG P0
(before treatment began). [*p<0.05 compared to NGP0; ǂp<0.05 compared to
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respective NG passage for HG cultured cells]. (B) SIRT1 enzyme activity was
reduced in HG in BREC (P8, data normalized to NG). (NG = 5 mM; HG = 25 mM
glucose; P = passage number). [*p<0.05 compared to NGP8].

Figure 2.7 SIRT (1-7) mRNA reduction with increasing passage number is
augmented with HG treatment in HUVECs. (A) SIRT (1-7) mRNA expressions
are decreased in large vessel endothelial cells (HUVEC) with increasing
passages and with HG it is escalated (analyzed by quantitative Real Time RTPCR). mRNA levels are expressed as a ratio to β-actin and normalized to
baseline controls, NG P0 (before treatment began). [*p<0.05 compared to NGP0;
ǂp<0.05 compared to respective NG passages for HG cultured cells]. (B) SIRT1
enzyme activity was reduced in HG in HUVEC (P11, data normalized to NG).

59

[*p<0.05 compared to NGP11]. (NG = 5 mM; HG = 25 mM glucose, P = passage
number).

2.3.3 SIRT1 activators reduce glucose induced accelerated aging.
As SIRT1 enzyme is significantly reduced in HG induced oxidative stress
and aging, we investigated whether SIRT1 activators can rescue such process.
Both resveratrol and BML278 significantly increased SIRT1 enzyme activity
(Figure 2.8C) and reduced the sign of aging in HG as seen from reduced β-gal
positivity (Figure 2.8A and B). As expected, SIRT1 activators reduced total ROS
levels in the HG treated cells compared to the controls (Figure 2.8D).
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Figure 2.8 Chemically induced activation of SIRT1 reduces oxidative stress in
HG treated endothelial cells. (A) SA β-gal staining of HMEC (P1) with resveratrol
and BML278 treatment. β-gal positivity was reduced with SIRT1 activators in HG
treated cells compared to controls. [Scale bar represent 100µm for all
micrographs]. (B) Quantification of β-gal positivity. (C) SIRT1 activators
significantly increased the enzyme’s activity and reduced (D) total ROS levels in
HG. (E) FOXO1 DNA binding activity was reduced in the nuclear fractions of
HMEC with SIRT1 activators along with increased (F) MnSOD levels. (G)
Western blot analysis of acetylated FOXO1 shows HG induced increase in AcFOXO1 level was corrected with SIRT1 activators. HG caused (H) nonsignificant
change in TERT mRNA expression, however (I) telomerase activity was
significantly reduced in the ECs and such reductions were prevented with SIRT1
activators. mRNA levels are expressed as a ratio to β-actin. All data were
normalized to NG. Osmotic controls with L-glucose had no effect. [*p<0.05,
**p<0.01 compared to NG; ǂp<0.05 compared to HG].

2.3.4 SIRT1’s action in ECs is mediated through FOXO1.
To elucidate the mechanism of HG induced SIRT1 mediated oxidative
stress and aging pathway, we looked into FOXO1, a major regulator of MnSOD
and also a target of SIRT1 [17, 23, 24]. We observed FOXO1’s DNA binding
activity in nuclear fractions of HMEC was reduced in HG and effectively rescued
by the SIRT1 activators (Figure 2.8E). In parallel, investigation of MnSOD levels
in these samples correlated with the reduced FOXO1 activity levels (Figure
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2.8F). Finally Western blot analysis demonstrated, HG induced increased
acetylated FOXO1 (Ac-FOXO1) levels were efficiently reduced with SIRT1
activators (Figure 2.8G).

Together these results supported SIRT1 regulated

MnSOD pathway in the ECs during HG induced rapid aging.
We further examined TERT mRNA expressions and telomerase activity in
the ECs with SIRT1 activators. In passage 1 although TERT mRNA was nonsignificantly reduced, telomerase activity were reduced significantly in HG and
such reductions were prevented by SIRT1 activators (Figure 2.8H and I).

2.3.5 FOXO1 inhibitor or SIRT1 silencing in NG mimics the HG
effects.
To investigate the role of FOXO1 in such pathway further, we treated
HMECs with a commercially available FOXO1 inhibitor (AS1842856) in NG. As
expected FOXO1 inhibitor reduced FOXO1 DNA binding (data not presented)
and subsequently reduced the MnSOD levels (Figure 2.9B). This led to an
increase in ROS levels and induced early senescence as seen from increased βgal positivity (Figure 2.9A and C). In addition, FOXO1 inhibitor dampened the
preventative effects of resveratrol on glucose-induced aging and oxidative stress,
supporting the relationship of SIRT1 and FOXO1 (Figure 2.9A-C). Silencing of
SIRT1 expression with siRNA (>50% reduction in mRNA expression, data not
shown) in NG also showed similar effects and mimicked the HG effects (Figure
2.9D and E). These findings confirmed our earlier findings and the specificity of
SIRT1 and FOXO1 in the rapid aging pathway in these ECs.
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Figure 2.9 SIRT1 knockdown or FOXO1 inhibition in NG induces signs of early
aging mimicking the HG treatment. (A) Early senescence was induced with
FOXO1 inhibitor (AS1842856) in NG, and the rescue of senescence with
resveratrol in HG disappeared with FOXO1 inhibitor, as evidenced by SA-β gal
stain (HMECP1). (B) In NG, AS1842856 reduced MnSOD and increased (C)
ROS levels; it also hindered the preventative effect of resveratrol in HG regarding
these parameters. [*p<0.05, **p<0.01 compared to NG; ǂp<0.05 compared to
HG; ┼p<0.05 compared to HG+Resveratrol]. (D) SIRT1 knockdown with siRNA
induced senescence in NG as seen using SA-β gal stain (HMECP1). (E) Such
knockdown also increased ROS levels. siRNA1 and siRNA2 represent separate
experiments using two different siRNAs. (F) Glucose induced increased SA β-gal
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positivity was reduced with resveratrol. However SIRT1 siRNA transfection
prevented such effect. (G) Analysis of SIRT1 mRNA level showed such effect of
resveratrol is mediated through SIRT1. mRNA levels are expressed as a ratio to
18s normalized to controls. (H) Glucose induced increased ROS production was
prevented by resveratrol. However such preventative effects were partially lost
with SIRT1 siRNA transfection. [*p<0.05, **p<0.01 compared to NG; ǂp<0.05
compared to HG; ┼p<0.05 compared to HG+Res.+scramble]. (NG = 5 mM; HG
= 25 mM glucose, P1 = passage 1).

[Scale bar represent 100µm for all

micrographs].
We then performed some additional experiments using SIRT1 siRNA in
ECs following SIRT1 activation with resveratrol. We treated HMECs with SIRT1
siRNA for 24 hrs following treatment with resveratrol for 48 hrs. We found the
siRNA reversed the effect of resveratrol on mRNA expression, oxidative stress
and aging (Figure 2.9F-H). This re-demonstrated the SIRT1 mediated aging in
the ECs in hyperglycemia.

2.3.6 SIRT1 and p300 have a balancing role on each other.
In order to explore the relationship of SIRT1 with other molecules in HG
induced accelerated aging, we investigated possible association between SIRT1
and p300. Since SIRT1 is a HDAC and actions of deacetylases are balanced by
HATs, we examined p300, a well characterized HAT. To investigate such
phenomenon, we knocked down SIRT1 in HMECs using siRNA and examined
p300 mRNA expression and vice versa (Figure 2.10A and B). We were able to
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achieve more than 50% reduction of the specific mRNAs following the
transfections (data not shown). SIRT1 silencing increased p300 mRNA
expression in both NG and HG treated cells (Figure 2.10A). On the other hand,
p300 silencing had no significant effect on basal SIRT1 mRNA level but reversed
glucose induced reduction of SIRT1 expression indicating a possible regulatory
role on each other (Figure 2.10B). To explore this relationship further we
performed additional experiments investigating the downstream molecules
(Figure 2.10C-F). We found p300 silencing in HG lead to a significant increase in
FOXO1 DNA binding activity and subsequent MnSOD level compared to controls
(Figure 2.10C and D). In addition, glucose induced increase of ROS and β- gal
positivity were also reduced with p300 siRNA (Figure 2.10E-G). These findings
together indicate that both SIRT1 and p300 regulate oxidative stress pathway in
ECs through FOXO1.
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Figure 2.10 SIRT1 and p300 regulate each other in microvascular endothelial
cells.

(A) Quantitative Real Time RT-PCR analysis showed HG upregulated

p300 mRNA and such effects are augmented by SIRT1 knockdown with siRNA.
(B) HG induced downregulation of SIRT1 mRNA expression was corrected with
p300 knockdown with siRNA. mRNA levels are expressed as ratio of 18s
normalized to NG. (C) p300 siRNA reduced total ROS levels in HG by increasing
(D) FOXO1’s DNA binding activity subsequently increasing (E) the MnSOD
levels. (F, G) Microscopic photographs and quantitative analysis showed glucose
induced increased SA β-gal positivity is effectively prevented by p300 siRNA.
Data normalized to NG. (NG = 5 mM; HG = 25 mM D-glucose, OSM = 25 mM Lglucose, P1 = passage1). [*p<0.05 and **p<0.01 compared to NG; ǂP<0.05 and
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ǂǂp<0.01 compared to HG. Scale bar represent 100µm for all micrographs.
siRNA1 and siRNA2 represent separate experiments using two different siRNAs].

2.3.7 Diabetes causes accelerated aging in kidney.
Finally, in order to investigate if the findings in vitro is reflected in vivo, we
used a well-established animal model, STZ induced C57BL/6 mice. Diabetic
animals showed high blood glucose (23.43 ± 3.27 mmol/L vs. controls 7.3 ± 0.93
mmol/L, p<0.001) and reduced body weight (22.50 ± 1.11 gm vs. controls 30.25
± 2.04 gm, p<0.003). Urinary albumin concentration was increased (0.58 ± 0.07
µg/mL vs. 0.21 ± 0.07 µg/mL in control, p<0.009) along with increased serum
creatinine in the diabetic animals (0.52 ± 0.08 mg/dL vs. controls 0.18 ± 0.04
mg/dL, p<0.02). Kidney tissues from diabetic mice showed increased β-gal
positivity compared to the controls, supporting our in vitro findings (Figure 2.11A
and B). This was further demonstrated as MnSOD levels, FOXO1 transcriptional
activity, SIRT1 mRNA expression and enzyme activity were significantly reduced
in kidneys of the diabetic animals along with an increased p300 protein levels in
these tissues (Figure 2.11C-G).
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Figure 2.11 Diabetes causes accelerated aging in mice kidney. (A) SA β-gal
staining of kidney tissue of STZ induced diabetic mice at 2 and 4 months
showing increased positivity with uncontrolled diabetes. Arrow indicates β-gal
positive cells. (B) Quantification of β-gal staining of the kidney tissue. Data
presented as β-gal positivity/view (n = 10 image). (C) Shows reduction of
MnSOD levels in kidney tissues of the diabetic animals following 2 and 4 months.
(D) mRNA analysis confirmed downregulation of SIRT1 expressions in the kidney
tissues of these animals. mRNA levels are expressed as a ratio to 18s
normalized to controls.

(E) FOXO1 DNA binding and (G) SIRT1 enzyme

activities are reduced in the kidney tissues in diabetes. (F) Western blot analysis
showed increased p300 protein levels in the kidneys in diabetes. Data

68

normalized to controls. [*p<0.05 compared to control animals. Scale bar
represents 100 µm for all micrographs].
We further examined renal tissues from type 2 diabetic mice that were
hyperglycemic and obese (data not shown). We found reduced MnSOD level
following 2 and 4 months of diabetes in the kidney tissues of these animals
(Figure 2.12A). mRNA analysis further showed reduced SIRT1 expression in
these tissues (Figure 2.12B). In addition FOXO1 DNA binding activity was
reduced in the kidneys of these mice (Figure 2.12C).

Figure 2.12 Oxidative stress and associated changes are present in the kidneys
and retinas of diabetic animals. (A) MnSOD levels were reduced in kidneys of
db/db mice following 2 and 4 months of diabetes indicating increased oxidative
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stress. (B, C) SIRT1 mRNA expression and FOXO1 activity in kidneys of db/db
mice were reduced compared to controls. (D) SA β-gal staining of type 1 diabetic
mice retina showed increased positivity in retinal blood vessels following 2
months of diabetes. [Scale bar represent 50 µm for all micrographs]. Arrow
indicates retinal blood vessels. (E) Such changes were associated with reduced
MnSOD level in these tissues. (F, G) Shows reduction of SIRT1 mRNA
expressions in retinal tissues of both type 1 and 2 diabetic mice. mRNA levels
are expressed as a ratio to 18s normalized to controls. [*p<0.05 compared to
control animals].

2.3.8 SIRT1 expression is reduced in retina with type 1 and type 2
diabetes.
Furthermore, we examined SIRT1 mRNA expression in retinas of the type
1 and 2 diabetic animals. Retinal SIRT1 mRNA expressions were reduced in
both models following 2 months of diabetes and the effects were pronounced
after 4 months (Figure 2.12F and G). Further, SA β-gal staining of mice retina
with type 1 diabetes showed increased positivity in the blood vessels following 2
months of diabetes, along with reduced antioxidant levels in these tissues (Figure
2.12D and E).

2.4

Discussion
This study demonstrates that hyperglycemia accelerates aging both in

vitro and in vivo. Although some studies have previously been performed [35] on
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ECs investigating the effects of HG exposure for short term periods (24 to 72 hr),
no study has yet been reported on chronic HG exposure of these cells, to
simulate the process of chronic hyperglycemia in an in vitro setting. We
simulated chronic hyperglycemia in the ECs with HG and propagated them in HG
for weeks or even months until the cells stopped proliferation completely for more
than 2 weeks. Such design allowed us to examine glucose induced accelerated
aging process amongst ECs of different origins. We have seen signs of cellular
senescence by SA β-gal positivity early in microvascular ECs and retinal ECs.
However this process was slower in large vessel ECs. The differentiated ECs
were more susceptible to hyperglycemia induced damage compared to HUVEC,
which is more close to progenitor cells in terms of differentiation [36] and are a
better survivor in hyperglycaemia. We have demonstrated that such process was
associated with increased oxidative stress.
Molecular diversity in the genetic level in ECs of various origins has been
studied before [37,38]. It has been shown that the gene expression profiles of
ECs from large vessels are different from those of micro-vessels [39]. In keeping
with these findings our study further demonstrated and elaborated some
structural and functional significance of these type of changes.
We have shown an important role played by SIRTs in this study. Since the
discovery of SIRTs, interests in these deacetylases have generated multiple lines
of evidences indicating SIRTs as evolutionarily conserved regulators of lifespan
[9, 18-21,40]. SIRTs regulate physiological response to metabolism and stress,
the two key factors affecting the aging process. We found all SIRT1-7 mRNA
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expressions were consistently reduced with the accelerated aging process in
hyperglycemia. Although isolated SIRT alterations have been demonstrated in
various studies [19, 20, 41-43], such comprehensive analysis of SIRTs have not
been done. More interestingly, the level of SIRTs reduction paralleled that of βgal positivity and such changes were prevented by SIRT activators indicating an
important relationship between SIRTs and aging.
SIRT1, the leading enzyme in the SIRT family is found both in the
cytoplasm and nucleus and has been found to have protective roles in stress
resistance and cell survival in various diseases [41, 44, 45]. This study showed
glucose induced alteration of downstream mediators of SIRT1, such as FOXO1
were corrected by SIRT1 activators further establishing the crucial role of SIRT1
in this process. The regulatory role of SIRT1 and p300 was further interesting.
p300 and SIRT1 regulates each other as silencing one gene lead to increased
expression of the other gene producing downstream affects. Other studies have
shown, in a different model, p300 acetylates and activates PPAR-γ leading to its
binding to SIRT1 promoter, thus decreasing SIRT1 expression [44]. Hence both
direct and indirect relationship between these two molecules may exist in the
ECs.
We have previously shown that p300 regulates multiple transcription
factors and proteins [6, 16]. Other studies have also shown acetylation of FOXO1
by p300 facilitates its phosphorylation by Akt ultimately exporting it from the
nucleus with chaperon 14-3-3 protein [24, 46]. In line with that, this study further
showed HG induced upregulation of p300 leads to attenuation of FOXO1 DNA
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binding activity in the ECs. This led to a reduction in MnSOD level, a known
target gene of FOXO1 [27] and increased oxidative stress in the ECs.
Furthermore, silencing p300 with siRNA corrected the MnSOD reduction and
downstream changes in hyperglycemia, confirming such pathway.
On the other hand as FOXO1 deacetylation by SIRT1 is necessary for its
retention in the nucleus [10, 29], we also found increased FOXO1 DNA binding
with SIRT1 activators, which increased SIRT1 enzyme activity and reduced SA
β-gal positivity. Additionally, both FOXO1 inhibitor and SIRT1 siRNA was able to
induce early senescence in NG, and mimicked the HG effect in the ECs.
Together, these results indicate an important mechanistic pathway of oxidative
stress and aging in HG, mediated through FOXO1 and regulated by SIRT1 and
p300.
In keeping with the in vitro studies, STZ induced diabetic mice showed
increased β-gal positivity in the kidneys following 2 & 4 months of uncontrolled
diabetes. The retina showed increased signs of aging following 2 months of
diabetes. This was accompanied by significantly reduced antioxidant levels in the
tissues. In addition, SIRT1 mRNA was found to be significantly reduced in kidney
and retina of both type 1 and type 2 diabetic mice.
In summary, this study showed chronic hyperglycemia accelerated aging
process through a novel SIRT1 and p300 regulated pathway. We demonstrated
HG induced reduction in SIRT1 lead to increased oxidative stress mediated
through FOXO1 which was prevented by SIRT1 activation. We further
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demonstrated p300 negatively regulates such pathway, as silencing p300
mimicked resveratrol’s effect. Identification of such novel mechanisms will allow
us to better understand the pathogenesis of diabetic complications as well as
aging and eventually help to find potential therapeutic treatment.

2.5
1.
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3

miR-195 regulates SIRT1 mediated changes in
diabetic retinopathyb

Rokhsana Mortuza, Biao Feng and Subrata Chakrabarti.Department of
Pathology, Schulich School of Medicine & Dentistry, Western University, London
ON Canada.

In this study our aim was to investigate SIRT1 regulation by miR-195 in
diabetic animals. We investigated the role of miR-195 in glucose-induced SIRT1
mediated changes in the ECs and retinas of type 1 diabetic rats.

bA

version of this chapter have been published: Mortuza R, Feng B, Chakrabarti

S. miR-195 regulates SIRT1-mediated changes in diabetic retinopathy.
Diabetologia. 2014;57(5):1037-46. doi: 10.1007/s00125-014-3197-9. Copyright ©
2014, Springer-Verlag Berlin Heidelberg. The article is being reused with kind
permission from Springer Science and Business Media.

79

3.1

Introduction
Diabetic retinopathy is a growing problem worldwide with no specific

medical treatment. In diabetic retinopathy, ECs of the retinal microvessels
undergo a series of changes in response to hyperglycemia causing activation of
several transcription factors [1-5]. Such processes lead to alteration of various
gene expressions resulting in structural and functional damages [6]. Glucoseinduced oxidative stress mediated increased production of extracellular matrix
(ECM) proteins such as fibronectin (FN) is a major characteristic feature of
diabetic retinopathy. Glucose-induced increased FN synthesis in ECs and
diabetes-induced augmented FN productions in the retina have been
demonstrated previously [7-14]. It is of interest to know that FN upregulation is a
common finding in endothelial and tissue aging [15-19].
Researchers have found SIRT1, the longevity gene, play crucial role in
regulating cell cycle, survival, metabolism and development across species since
its identification [20-25]. We have demonstrated glucose-induced increased
oxidative stress causes rapid aging in ECs and retinas in diabetes [26]. Such
processes are mediated through alteration of Sirtuins (SIRTs), a family of NAD+
dependent class III histone deacetylases. Furthermore, transcriptional coactivator p300 regulates such pathway by modifying both SIRT1 (leading enzyme
in the SIRT family) and FOXO1 (forkhead O group of transcription factor) and
altering the antioxidant levels in these ECs [26]. However, other post
transcriptional ways of SIRT1 regulations also holds tremendous potential.
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With the discovery of miRNAs, research on SIRT1 regulation has
progressed and several miRNAs have been found to regulate SIRT1 in various
tissues and disease conditions [27]. miRNAs are highly conserved small (19-24
nucleotides), non-coding RNAs that regulate gene expression at the post
transcriptional level, by binding with 3’UTRs (untranslated regions) of the specific
mRNAs, causing their degradation or translational repression [27-29]. Over one
third of genes are estimated to be regulated by miRNAs. miRNAs may play roles
in many biological processes, including development of metabolic diseases such
as diabetes [27-35].
Although several researches have been conducted on miRNA mediated
regulation of SIRT1 in various physiological and pathological conditions [25], no
studies have been conducted on such regulation in diabetic retinopathy. In this
study we investigated the role of a specific miRNA, miR-195 in regulating SIRT1
in diabetic retinopathy. miR-195 is upregulated in circulation in patients with
hypertension, metabolic syndrome and glucose intolerance [36]. Similar
increases were seen in kidney and liver tissues of diabetic animals [37, 38]. In
cardiomyocytes, miR-195 was found to inhibit SIRT1 and thus promote palmitateinduced apoptosis [39]. miR-195 deregulation has been associated with several
other

diseases,

with

upregulation

in

multiple

cancers,

hypertrophic

cardiomyopathy and pre-eclampsia [40, 41]. In line with these research, our
previous microarray analysis [42] showed miR-195 upregulation in glucose
exposed ECs and in the retinas of diabetic rats. As SIRT1 is a possible target of
miR-195 we explored this relationship further in diabetic retinopathy.
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Since SIRT1 is a possible target of miR-195 (www.mirbase.org,
www.microrna.org), we investigated whether miR-195 alteration occurs in
diabetic retinopathy, and if such alterations causes EC aging in hyperglycemia.
Microvascular ECs are the major target of glucose mediated damages in the
retina, hence we examined human retinal and dermal microvascular ECs
(HRECs and HMECs), to characterize glucose-induced miR-195 mediated
regulation of SIRT1 and downstream cellular changes. We further expanded the
study to investigate retinas of streptozotocin (STZ) induced type 1 diabetic
animals [42, 43].

3.2

Materials and methods

3.2.1 Cell culture
HRECs were obtained from Olaf Pharmaceuticals (Worchester, MA) and
HMECs were obtained from Lonza, Inc. (Walkersville, MD). Cells were grown in
EC basal medium 2 (EBM-2, Lonza, Walkersville, MD) and trypan blue dye
exclusion test was used to examine cell viability as described [42-44]. The cells
were passaged in 6 well plates (Corning, Acton, MA) and treated with normal
glucose (NG, 5 mmol/l D-glucose) or high glucose (HG, 25 mmol/l D-glucose) or
osmotic control (OSM, 25 mmol/l L-glucose) for 72 hours. Human embryonic
kidney (HEK293A) cells were obtained from ATCC (Manassas, VA) and were
used as previously described [42-44]. Reagents were obtained from Sigma
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Chemicals (Sigma, Oakville, ON) unless specified otherwise. All experiments
were conducted with 6-10 replicates.

3.2.2 mRNA extraction and quantitative analysis
TRIZOL™ (Invitrogen, Burlington, ON) was used to isolate RNA [42-44].
Real Time RT-PCR was performed using High Capacity cDNA Reverse
Transcription kit (Applied Biosystems, Foster city, CA) , Qiagen One Step RTPCR kit with custom made SIRT1 and FN primers and LightCycler™ (Roche
Diagnostics Canada, Quebec) as described [26, 43]. The data were normalized
to 18sRNA [26, 43].

3.2.3 miRNA extraction and analysis
As described [42, 43], mirVana miRNA isolation kit (Ambion, Inc., Austin,
TX) was used to extract miRNAs from cells and tissues. Real time RT-PCR was
conducted with a reaction volume of 20 µL as described [42, 43].

3.2.4 miRNA mimic or antagomir transfection
ECs were transfected with miRIDIAN microRNA-195 mimic or antagomir
(20 nmol/l) (Dharmacon Inc., Chicago, IL) using Lipofectamine2000 (Invitrogen,
Burlington, ON). Scrambled controls were used in parallel [42, 43].
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3.2.5 Adenoviral forced-expression of SIRT1 and SIRT1 gene
silencing
SIRT1 adenovirus (devoid of 3’UTR) and null vector was obtained from
ABM (Richmond, BC, Canada) and amplified in HEK293A cells. ECs were
transduced with the adenovirus (with or without glucose) and following 72 hours
of treatment samples collected.

To silence SIRT1, transfection of small

interfering RNA (siRNA) was performed as described by us earlier [26].

3.2.6 Luciferase Reporter Assay for Targeting SIRT1-3'UTR
The luciferase vector including 3′UTR of SIRT1 (1080 bp) containing the
SIRT1-miR-195 response elements (wt-Luc-SIRT1) and the mutant (mu-LucSIRT1) were purchased from Norclone Biotech Laboratories (London, ON,
Canada). Plasmid DNA (wt-Luc-SIRT1 or mu-Luc-SIRT1, β-galactosidase control
vector) and miR-195 mimic or scrambled oligonucleotide were co-transfected in
HRECs for 48 hours. Luciferase activity was measured using the Dual-Light
Chemiluminescent

Reporter

Gene

Assay

System

(Applied

Biosystems,

Burlington, ON) and SpectraMax M5 (Molecular Devices, Sunnyvale, CA) and
normalized by measuring β-galactosidase activity.

3.2.7 MnSOD, FN ELISA and SIRT1 enzyme activity assay
MnSOD (manganese superoxide dismutase) and FN ELISA were
performed using commercially available kits [26, 43]. As described earlier, [26]
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SIRT1 enzyme activity was measured as per the manufacturer instructions
(Sigma, Oakville, ON).

3.2.8 Animal Experiments
Animal experiments were conducted following guidelines specified by the
Canadian Council of Animal Care. Protocols were approved by the Western
University Animal Care and Veterinary Service. The investigations were in
accordance with NIH publ. no. 85-23, revised 1996.
Sprague-Dawley rats (~175g, 6 weeks, male) were obtained (Charles
River, Wilmington, MA). Diabetes was induced by a single intraperitoneal
injection of streptozotocin (STZ) (65 mg/kg, in citrate buffer, pH 5.6). Control
animals received equal volume of citrate buffer. Diabetes was determined as a
blood glucose level >20 mmol/l on 3 successive days (Abbott Diabetes Care,
Alameda, CA). The animals were fed on a standard diet with water ad libitum and
monitored daily [42, 43]. A group of diabetic rats (n=7/group) received weekly
intravitreal injections of 1.5 µg miR-195 mimic or antagomir in lipofectamine
reagent in one eye. The other eye received scrambled control. They were
sacrificed one week after the fourth injection. Retinal tissues were collected, snap
frozen and were stored at −80°C until further analysis.
To assess intravitreal miRNA penetration efficiency DY547 (red
fluorescent dye) tagged miRNA scramble transfection control (Dharmacon Inc.,
Chicago, IL) was injected intravitreally and retinal tissues were collected from
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sacrificed animals at 2 hr, 4hr, 8hr and 24hr following injection and snap frozen.
DY547 tagged RNA has previously been shown to penetrate in the retina
following intravitreal injection [45].

Slides from the same sections were

counterstained with H&E for orientation.

3.2.9 In situ Hybridization
As described earlier [43, 46] 5' and 3' double DIG-labelled custom-made
mercury LNA™ miRNA detection probes (Exiqon, Vedbaek, Denmark) were used
to detect miR-195 expression using in situ hybridization(ISH) Kit (Biochain
Institute, Hayward, CA) in retinal tissue sections. Scrambled probe and no-probe
were used as controls.

3.2.10 Immunohistochemistry
IgG stainings were performed on frozen retinal sections using anti-rat IgG
(ebioscience, Sandiego, CA) with hematoxylin counterstain as described [42, 43].
Quantification was done in a masked fashion using an arbitrary scale (0 = no
extravascular stain of retina, 1 = mild extravascular stain,

2 = moderate

extravascular stain, 3 = marked extravascular stain).

3.2.11 SA β-GAL staining, phase contrast & fluorescent microscopy
Cells or frozen retinal sections were stained with SA β-GAL staining kit
(abcam, Cambridge, MA). Retinal slides were counterstained with H&E for
orientation. From each specimen, positive (blue) cells were photographed with
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phase contrast inverted microscope [26]. They were counted per 10 microscopic
fields at 20X magnification and presented as % of total number of cells [26].
Tissue slides were quantified based on staining intensity at 60X magnification as
described [47]. Fluorescent microscopies of frozen retinal sections were
performed with TRITC filter at 20X magnification.

3.2.12 Western Blot
Western blot analysis was conducted according to the standard protocol
[10] using SIRT1 & β-Actin antibody (Santa Cruz Biotechnology, Santa Cruz,
CA).

3.2.13 Statistical analysis
Data are expressed as mean ± SEM, normalized to controls (n≥6). The
statistical significances were analyzed by one or two way ANOVA followed by
Tukey’s HSD post hoc correction and the two tailed Students t test as
appropriate (PASW Statistics 18, IBM, Canada). A p value < 0.05 was
considered statistically significant.

3.3

Results
In the initial screening of SIRT1 targeting microRNAs using our previously

published array data of retinal tissues of normal and diabetic animals [42], we
found miR-195 expression was increased almost 3 fold in the retinal tissues of
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the diabetic animals (Table 3.1). Other SIRT1 targeting miRNAs such as miR34a, miR-138, miR-9 were reduced, and miR-217, miR-199a, miR-200a and miR132 expression levels were unchanged (Table 3.1). On the basis of our initial
findings we further investigated the role of miR-195.
Table 3.1 Fold changes of SIRT1 targeting miRNAs.

miRNA

Fold change (compared to control, p≤0.05)

miR-195

2.8

miR-34a

0.53

miR-138

0.51

miR-9

0.43

miR-217

1.07

miR-199a

1.04

miR-200a

0.93

miR-132

1.02

3.3.1 High glucose causes upregulation of miR-195 and SIRT1
downregulation in the ECs.
Based on the hypothesis that glucose-induced SIRT1 downregulation is
mediated by miR195, we investigated HRECs exposed to 5 (NG) and 25 (HG)
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mmol/l D-glucose for 72 hrs. These concentrations are based on our previous
dose dependent analysis of SIRT1 mRNA and protein expression [26].

We

confirmed reduction of SIRT1 mRNA and enzyme activity following incubation
with HG but not by 25 mmol/l L-glucose (osmotic control, OSM, Figure 3.1a and
3.1c) in HRECs. We then extracted miRNA from these cells. Quantitative Real
Time RT-PCR analysis of the ECs in HG confirmed significant upregulation of
miR-195 compared to 5 mmol/l glucose. No effects were seen following
incubation with 25 mmol/l of L-glucose (Figure 3.1b).

Figure 3.1 miR-195 regulates SIRT1 in ECs in hyperglycemia. (a) SIRT1 mRNA
and (b) miR-195 expressions in HRECs following exposure to HG and NG with
miR-195 mimic and antagomir transfections. (c) SIRT1 enzyme activity and (d)
protein levels with miR-195 mimic and antagomir transfections. (b) Efficiency of
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miR-195 antagomir and mimic transfection in HRECs compared to scrambled
controls. [HRECs= Human retinal microvascular endothelial cells, HG= 25 mmol/l
glucose, NG= 5 mmol/l glucose, OSM= 25 mmol/l L-glucose. Scramble=
scrambled miRNAs, 195= miR-195 mimics, 195(A)= miR-195 antagomirs, *=
significantly different from NG, †= significantly different from HG. miRNA levels
are expressed as a ratio to RNU6B (U6); mRNA levels are expressed as a ratio
to 18s. All data are normalized to 5 mmol/l glucose. n=6] (e) Alignment of SIRT13’UTR (and mutated SIRT1-3’UTR) sequence with mature miR-195 based on
bioinformatics

predictions

(www.targetscan.org,

www.microrna.org,

www.mirbase.org). The 5' end of the mature miR-195 is the seed sequence and
has perfect complementarity with six nucleotides of the 3'UTR of SIRT1. In the
mutated sequence (small caps) such complementarity was lost. (f) Luciferase
reporter assay in HRECs, showing dose dependent binding of SIRT1-3'UTR with
miR-195. Mutated (mut) SIRT1-3'UTR abrogated the inhibitory effects of miR195. [Relative luciferase activities were expressed as luminescence units,
normalized for β-galactosidase expression, *= significantly different from vector
or mut. Vector= SIRT1-3’UTR luciferase plasmids+β-galactosidase plasmids,
SIRT1

mut=

mutated

SIRT1-3’UTR

luciferase

plasmids+β-galactosidase

plasmids. n=6]. (g) shows cellular MnSOD levels with miR-195 antagomir
transfection in HG, n=6.
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3.3.2 Glucose-induced SIRT1 reduction in the ECs is mediated by
miR-195.
We then proceeded to explore functional significance of such glucoseinduced miR-195 upregulation with respect to SIRT1 expression. To find a
cause-effect relationship, we transfected cells in 25 mmol/l glucose with miR-195
antagomir. Transfection efficiencies, assessed by measuring miR-195 expression
showed substantial reduction in intracellular miR-195 expression compared to
scrambled miRNA transfection (Figure 3.1b). Such reduction could be attributed
by degradation of the miRNA following binding with antagomir [48]. Additionally
irreversible binding of antagomirs with the miRNAs may further prevent
amplification.
Such transfection effectively rescued glucose-induced SIRT1 downregulation. No
such effects were seen with scrambled miRNAs (Figure 3.1a, c). On the other
hand, transfection of the ECs in 5 mmol/l glucose with miR-195 mimic
downregulated SIRT1 mRNA production and enzyme activity mimicking the
effects of 25 mmol/l glucose (Figure 3.1a-c). Furthermore, SIRT1 protein and
enzyme analysis showed glucose-induced reduced SIRT1 enzyme activity in the
ECs is prevented by miR-195 antagomir transfection (Figure 3.1c, d). On the
other hand, transfection of HRECs in NG with miR-195 mimic caused effects
similar to HG by reducing SIRT1 levels in these ECs (Figure 3.1a-d).
In parallel, we conducted similar experiments in HMECs (to examine
whether the changes are unique to HRECs or universal to other microvascular
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ECs) which showed similar effects confirming the changes observed in HRECs
(Figure 3.2a-d).

Figure 3.2 miR-195 regulates glucose-induced SIRT1 mediated aging changes in
HMECs. Human dermal microvascular endothelial cells (HMECs) showed
glucose-induced (a) miR-195 upregulation (n=10) and (b) SIRT1 downregulation.
(b-d) Transfection of HMECs with miR-195 antagomirs normalized HG induced
downregulation of SIRT1 mRNA and enzyme activity; (c) shows efficiency of
miR-195 antagomir and mimic transfection. n=6. (e) Senescence associated SAβGAL staining of HMECs showed increased positivity with 25 mmol/l glucose
(HG) treatment compared to 5 mmol/l glucose (NG) and 25 mmol/l L-glucose
(OSM). MiR-195 antagomir transfection successfully prevented such signs of
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cellular aging. Such changes were not seen in cells transfected with scrambled
miRNA. Arrow indicates positive cell (blue). (f) Quantitation of SA-βGAL
positivity, n=10 image/treatment. (g) shows HG induced induced reduction of
cellular MnSOD levels were normalized with miR-195 antagomir transfection,
n=6. [Scramble= scrambled miRNAs, 195= miR-195 mimics, 195(A)= miR-195
antagomirs, *= significantly different from NG, †= significantly different from HG.
MiRNA levels are expressed as a ratio to RNU6B (U6); mRNA levels are
expressed as a ratio to 18s. All data are normalized to 5 mmol/l glucose.
MnSOD= manganese superoxide dismutase. Scale bar represent 100 µm for all
micrographs. Inset = magnified image showing cytoplasmic SA-βGAL positivity.]

3.3.3 miR-195 binds to 3’UTR of SIRT1 mRNA.
To examine direct binding of miR-195 with 3'UTR of the SIRT1 mRNA, we
did Luciferase assays in HRECs. We co-transfected miR-195 mimic with
Luciferase reporter plasmids having cloned miR-195 binding sites for SIRT13'UTR

or

mutated

SIRT1-3'UTR.

SIRT1-3'UTR

luciferase

activity

was

significantly repressed with such miR-195 overexpression, which was however
not seen with mutated SIRT1-3'UTR (Figure 3.1e, f and Figure 3.3a). These
results confirmed binding of miR-195 with 3'UTR of SIRT1 mRNA.
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Figure 3.3 Plasmid map showing (a) site of SIRT1- 3’UTR (wt/mut) insertion in
the vector (pMIR-Report-Luciferase plasmid) in regards to the luciferase assay.

3.3.4 miR-195 antagomir prevents HG-induced reduction of SIRT1
regulated antioxidant levels.
To investigate glucose-induced downstream functional alterations of such
miR-195 increase in ECs, we measured intracellular antioxidant levels. In
previous studies we have established such SIRT1 mediated changes in the ECs
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[26]. SIRT1 regulated antioxidant MnSOD analysis showed upregulation of this
enzyme with miR-195 inhibition (Figure 3.1g). Likewise, HMECs showed similar
effects of miR-195 inhibition in 25 mmol/l glucose (Figure 3.2g).

3.3.5 miR-195 antagomir averts FN upregulation in ECs.
Increased production of ECM protein FN is a characteristic feature of
diabetic retinopathy [7-14]. Hence we examined FN mRNA and protein level in
these ECs. miR-195 antagomir transfection (not scrambled controls) attenuated
HG-induced increased FN mRNA and protein levels in the ECs (Figure 3.4a, b).
Moreover, knockdown of SIRT1 with siRNA in NG showed glucose-like effect in
which there was an increase in FN mRNA and protein levels confirming such
regulation (Figure 3.4c and Figure 3.5a, b). Such effect was not seen with
scrambled siRNA treatment (Figure 3.4c and Figure 3.5a, b).
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Figure 3.4 SIRT1 forced-expression prevents glucose-induced FN upregulation in
ECs. (a) FN mRNA and (b) FN protein levels in HRECs with miR-195 transfection
in HG. (c) FN mRNA levels following SIRT1 knockdown with siRNA in NG in the
ECs. (d) SIRT1 enzyme activity with adenoviral overexpression in the ECs
confirming transfection efficiency at the functional level. (e) FN mRNA levels in
HG with Ad-SIRT1 transfection. (f) FN mRNA levels in NG with miR-195 mimic
and Ad-SIRT1 transfection. [HG= 25 mmol/l glucose, NG= 5 mmol/l glucose,
195= miR-195 mimics, 195(A)= miR-195 antagomirs, *= significantly different
from NG, †= significantly different from HG; mRNA levels are expressed as a
ratio to 18s normalized to NG. HRECs= human retinal microvascular endothelial
cells. All data normalized to controls. n=6]
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Figure 3.5 SIRT1 knockdown in NG increases FN protein levels in HRECs. (a)
SIRT1 knockdown efficiency with siRNA in NG shows significant reduction of
SIRT1 mRNA levels in the ECs and such reduction caused an increase in (b) FN
protein levels. Such increase is absent in scramble siRNA treated cells. (c, d)
Shows effect of miR-195 antagomir treatment in HRECs in passage 3 has
preventative effect against HG induced accelerated aging changes in these cells,
n=10 image/treatment. (e) Shows MnSOD level in HREC passage 3 following
miR-195 antagomir transfection. HG induced reduction of MnSOD level is
efficiently increased with such treatment in these ECs. [Scramble = scrambled
miRNAs. 195(A)= miR-195 antagomirs, HRECs = human retinal microvascular
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endothelial cells. *= significantly different from NG, †= significantly different from
HG. P3= passage 3, MnSOD= manganese superoxide dismutase. Data
normalized to NG. Scale bar represent 100 µm for all micrographs. Inset =
magnified image showing cytoplasmic SA-βGAL positivity. n=6]

3.3.6 SIRT1 forced-expression prevents FN upregulation in ECs.
We further wanted to see if forced-expression of SIRT1 can prevent FN
upregulation in ECs in hyperglycemia. We transfected HRECs with SIRT1
adenovirus and analysed the cells with Real Time RT-PCR (data not presented).
SIRT1 enzyme activity was increased following the transfection in HG treated
ECs compared to empty vector controls (Figure 3.4d). Such increase activity
normalized the HG induced FN upregulation in these cells (Figure 3.4e). In
parallel, we conducted similar experiments in HMECs which were in line with the
findings observed in HRECs (Figure 3.6a-d).
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Figure 3.6 SIRT1 forced-expression showed preventative effect against glucoseinduced damage in HMECs. Transfection of miR-195 antagomir prevented
glucose-induced upregulation of (a) FN mRNA and (b) protein levels in the
HMECs. (c) Adenoviral forced-expression of SIRT1 in the ECs increased the
enzyme’s activity both in NG (5 mmol/l glucose) and HG (25 mmol/l glucose)
confirming transfection efficiency at the functional level. Such increase in activity
were absent in null vector transfected ECs. Ad-SIRT1 transfected ECs showed
(d) attenuated upregulation of HG induced FN mRNA levels and (e) reduced
signs of aging with SA β-GAL stain. Arrow indicates positive cell (blue). (f)
Quantitation of SA β-GAL positivity, n=10 image/treatment. [195(A)= miR-195
antagomirs, *= significantly different from NG, †= significantly different from HG;
mRNA levels are expressed as a ratio to 18s normalized to NG. HMECs= human
dermal microvascular endothelial cells. All data normalized to controls. Scale bar
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represent 100 µm for all micrographs. Inset = magnified image showing
cytoplasmic SA β-GAL positivity. n=6]
We further conducted an additional experiment to see if the effects of miR-195
are reversible. We observed adenoviral overexpression of SIRT1 (plasmid
lacking the binding site of miR-195), reverses the miR-195 mimic induced
upregulation of FN mRNA levels in NG (Figure 3.4f). Such finding shows the
detrimental effects of miR-195 is reversible, and confirms miR-195 mediated
regulation of SIRT1 and downstream changes in these ECs.

3.3.7 miR-195 is overexpressed in the retina in diabetes.
We then moved to a well-established animal model to examine, if the
mechanisms seen in ECs are indeed involved in the development of retinal
microangiopathy.

We

used

STZ-

induced

diabetic

rats

demonstrating

hyperglycemia (serum glucose of diabetics 20.2±1.9 mmol/l vs controls 5.3±0.7
mmol/l, p<0.001) and reduced body weight (diabetics 299.0±59.2 g vs controls
460.8±13.2 g, p<0.001). Real Time RT-PCR analysis of retinal tissues of these
animals following 1 month of uncontrolled diabetes showed significant
upregulation of miR-195 (Figure 3.7a). It is of interest to note that, we have
previously shown in this model, diabetes causes increased ECM protein and
vasoactive factor expression at this time point [42, 43]. Such notion was further
confirmed by using in situ hybridization and LNA probes. In the retinas of diabetic
animals, miR-195 was overexpressed in the cells of inner and outer nuclear
layers, ganglion cell layers and ECs of the microvessels (Figure 3.7b).
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Figure 3.7 miR-195 is overexpressed in the retina in diabetes. (a) Rat retinal
miR-195 expressions in control and diabetic animals. (b) LNA-ISH analysis of
retinal tissues of control and diabetic animals. Blue chromogen shows miR-195 in
the cells of the inner nuclear layers (thin arrow), outer nuclear layers (thick
arrow), ganglion cell layers (arrowhead) and endothelial cells of the microvessels
(arrow, inset). Diabetic rat retina stained with scrambled miRNA probes lacking
such stain confirmed specificity of the miR-195 probe. Insets show enlarged view
of the retinal capillaries. (Scale bar = 50 µm for all micrographs). [*= significantly
different from control. miRNA levels are expressed as a ratio of RNU6B (U6)
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normalized to control. ALK Phos was used as chromogen (blue) with no counter
stain in LNA-ISH. n=7 eye/treatment]

3.3.8 Diabetes induced SIRT1 downregulation in the retina and its
downstream effects are mediated by miR-195.
To establish the functional consequence of miR-195 upregulation in the
retina, we investigated retinal SIRT1 mRNA and enzyme levels which is a target
for miR-195. Diabetes-induced miR-195 upregulation was associated with SIRT1
mRNA downregulation (Figure 3.8c). Simultaneously SIRT1 protein and enzyme
level was also reduced in the retina in diabetic rats (Figure 3.8d, e). To find a
cause-effect relationship, we performed intravitreal miR-195 antagomir injection.
Penetration efficiency of such drug delivery was confirmed with DY547 tagged
miRNA injection, which shows effective transfection of the miRNA in rat retinal
layers and microvessels following 2 hours of the injection (Figure 3.8a).
Intraretinal delivery efficiencies, assessed by measuring miR-195 expression in
the retina, showed reduction in retinal miR-195 expression (Figure 3.8b). Such
intravitreal miR-195 injection normalized diabetes-induced SIRT1 reduction in the
retinas of the treated animals (Figure 3.8c-e). We further measured antioxidant
level in the retinas. Diabetes-induced reduction of retinal MnSOD levels were
prevented with miR-195 antagomir injection (Figure 3.8f). No such prevention
was seen with injection of scrambled oligonucleotides or vehicles (Figure 3.8f). In
addition, injection of miR-195 mimic in control animals caused effects similar to
diabetes with reduced SIRT1 mRNA and MnSOD levels (Figure 3.8c, f).
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Figure 3.8 miR-195 antagomir treatment can ameliorate diabetes induced
reduction of antioxidant levels in retinal tissues. (a) Fluorescent microscopy
images of rat retinas following intravitreal injection of DY547 tagged miRNA and
vehicle demonstrating penetration. Arrows show various layers of rat retina. Inset
shows enlarged view of retinal microvessels.

(Scale bar= 100 µm for both

micrographs). (b) Retinal miR-195 expression following intravitreal injection of
miR-195 antagomir to assess efficiency of intravitreal delivery. (c) SIRT1 mRNA
levels in the rat retinas following intravitreal miR-195 antagomir treatments. (d)
SIRT1 protein level and (e) enzyme activity following such injections. (f) Shows
MnSOD levels in the retinal tissues of the control and diabetic animals following
miR-195 mimic and antagomir injections. [*= significantly different from control
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(Co), †= significantly different from diabetic (Di) or Di+Scramble. 195= miR-195
mimics, 195(A)= miR-195 antagomirs. miRNA levels are expressed as a ratio of
RNU6B (U6) normalized to control; mRNA levels are expressed as a ratio to 18s
normalized to control. MnSOD= manganese superoxide dismutase. DY547= red
fluorescent dye. n=7 eye/treatment]
We further expanded the study to see the downstream effects of miR-195
mediated increased oxidative stress and measured the level of FN protein in the
rat retinal tissue. We observed diabetes-induced upregulated FN protein levels in
the retina were reduced by intravitreal mir-195 antagomir injection. Retinal tissue
with scrambled miRNA treated animals did not show such effects (Figure 3.9a).

104

Figure 3.9 miR-195 antagomir prevents diabetes-induced increased FN protein
and vascular leakage in retina. (a) FN protein levels in rat retinal tissues with
intravitreal

miR-195

antagomir

injections

in

the

diabetic

animals.

(b)

Immunohistochemical stains on the rat retinas following miR-195 antagomir
treatment. Brown chromogen indicates IgG extravasation. (Hematotoxylin
counterstain). Arrow shows diffuse staining in the retina of the diabetic animal.
[195(A)= miR-195 antagomirs,

*= significantly different from control (Co), †=

significantly different from diabetic (Di) or Di+Scramble; Scale bar represent 50
µm for all micrographs. Data normalized to controls. Inset = magnified images of
retinal microvessels. n= 7 eye/treatment]
We

then

investigated

permeability

changes

and

measured

IgG

extravasation from the retinal vasculature using an IgG immunostaining. We
found diabetes-induced increased vascular permeability was reduced by the
miR-195 antagomir injection (Figure 3.9b). No extravascular IgG was seen in the
control animals (score= 0). Diabetic animals demonstrated a score of 2 to 3,
indicating increased extravasated IgG. Scores of 0 to 1 were noted in eyes
injected with the miR-195 antagomir, indicating prevention of diabetes-induced
increased vascular permeability by such treatment.

3.3.9 miR-195 antagomir prevents SIRT1 mediated EC senescence
in hyperglycemia.
As SIRT1 is an aging-associated molecule and we have previously shown
that the changes in diabetes are comparable to accelerated aging [26], we
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investigated additional downstream alterations of miR-195 increase and SIRT1
downregulation in ECs and retina. We stained the cells with SA β-GAL (a
lysosomal enzyme accumulated in senescent cell), an established marker for
assessing cellular senescence [26, 47]. miR-195 antagomir transfection (not
scrambled controls) prevented HG induced ECs aging, as evidenced by reduced
β-GAL positivity (Figure 3.10a, b and Figure 3.2e, f). Furthermore, HRECs
transfected with miR-195 mimic in NG caused cellular changes similar to HG
(Figure 3.10a, b). On the contrary, adenoviral overexpression of SIRT1 in HG
ameliorated such effects in the ECs (Figure 3.10a, b and Figure 3.6e, f).
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Figure 3.10 miR-195 inhibition halts glucose-induced SIRT1 mediated cellular
senescence in ECs. (a) Senescence associated SA β-GAL staining of HRECs in
HG and NG following miR-195 mimic, antagomir and with Ad-SIRT1 transfection.
Arrow indicates positive cell (blue). (b) Quantitation of SA β-GAL positivity, n=10
image/treatment. [Scale bar represent 100 µm for all micrographs. Inset =
magnified image showing cytoplasmic SA β-GAL positivity. HRECs = human
retinal microvascular endothelial cells. HG= 25 mmol/l glucose, NG= 5 mmol/l
glucose, OSM= 25 mmol/l L-glucose. *= significantly different from NG, †=
significantly different from HG.] (c) SA β-GAL staining of rat retinal sections
following intravitreal miR-195 antagomir treatment, n=10 image. Arrow shows
retinal inner nuclear layers. No counterstain. [Inset = magnified images of retinal
microvessels. Scale bar represent 50 µm for all micrographs. 195= miR-195
mimics, 195(A)= miR-195 antagomirs. *= significantly different from control, †=
significantly different from diabetic (Di) or Di+Scramble]
We expanded the study and investigated miR-195 mediated cellular
changes at a later passage [26]. miR-195 antagomir transfection in HRECs at
passage 3 showed reduction of cellular senescence along with increased
MnSOD level with such treatment (Figure 3.5c-e). In parallel, retinal tissues
stained with SA-βGAL showed increased positivity in the diabetic animals. Such
positivity was significantly reduced with intravitreal miR-195 antagomir treatment
in the retina, especially in ECs of the microvessels (Figure 3.10c). Scrambled
miRNA treated diabetic animals lacked such improvements (Figure 3.10c).
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3.4

Discussion
In this study we have shown a novel role of miR-195 in regulating

hyperglycemia induced changes in microvessels in diabetic retinopathy. Using
miR-195 antagomir transfection, we have demonstrated that diabetes-induced
SIRT1 downregulation and subsequent functional consequences can be
prevented by decreasing the availability of miR-195. We further verified the in
vitro findings in vivo, by injecting miR-195 antagomir intravitreally in STZ induced
type 1 diabetic rats, which showed such treatment prevented SIRT1 reduction in
these tissues following 1 month of uncontrolled hyperglycemia, and normalized
FN proteins levels in diabetes. Such role of miR-195 regulated, SIRT1 mediated
FN regulation and aging-like changes, in glucose-induced ECs and retina of
diabetic animals have not been reported earlier.
In diabetes, overproduction of superoxides by the mitochondrial electron
transport chain in the ECs causes DNA damage, activating several transcription
factors and altering multiple gene expressions [6, 9-11, 49]. We have
demonstrated that glucose-induced SIRT1 mediated downregulation of MnSOD
causes aging like changes in the ECs and retina in diabetes [26]. Such changes
are also regulated by transcriptional coactivator and histone acetyl transferase
p300 [26]. In this research, we have characterized another level of regulation of
glucose-induced SIRT1 downregulation and its downstream effects through
alteration of miR-195.

108

Several lines of evidence have recently been presented to demonstrate
that miRNAs play a significant role in a large number of cellular processes [2734]. Adding to such data, we have previously showed miR-200b & miR-146a
plays an important role in diabetic retinopathy through VEGF and FN modulation
respectively [42, 43]. Here we described the role of miR-195 causing SIRT1
downregulation in ECs, which also mediate aging-like changes, vascular
permeability and FN upregulation in diabetes. We investigated the mechanisms
at multiple levels of complexities. After the initial identification of miR-195
upregulation in the human retinal capillary ECs, we used miR-195 antagomir and
mimic to identify in vitro biological significance. We further observed similar
changes in human dermal microvascular ECs. We have also showed similar
alterations and functional significance of this mechanism in an established animal
model of diabetic retinopathy.
Several changes seen in chronic diabetic complications are similar to
normal aging process [7-19].

However, such changes are accelerated in

diabetes and we have demonstrated they are mediated by oxidative stress
induced SIRT alterations [26]. Increased FN production has been demonstrated
in aging [15-19]. Furthermore, augmented ECM protein such as FN production is
a characteristic feature of diabetic retinopathy and is a result of EC dysfunction
induced by hyperglycemia [7-14]. We and others have previously demonstrated
glucose-induced increased FN synthesis in the ECs and in the retina in diabetes
[7-14]. Such increased FN production can cause outside-in signaling and
alteration of vasoactive factors [14, 44]. This is the first study to demonstrate
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SIRT1 mediated FN regulations in diabetic retinopathy, which is modulated by
specific miRNA. These findings were further confirmed by SIRT1 forcedexpression in ECs, which showed reduced FN expression in high glucose. We
have shown that miR-195 regulates SIRT1 mediated FN alteration, further
establishing the importance of such mechanisms of tissue damage and potential
therapeutic role in diabetic retinopathy.
To our knowledge, there is no previous work characterizing the role of
miR-195 in diabetic retinopathy. Our findings are in keeping with previous reports
regarding

miR-195

where

it

was

found

to

prevent

palmitate-induced

cardiomyocyte apoptosis and was elevated in liver and kidney of diabetic animals
and in circulation of glucose intolerant patients [36-40]. It is to be noted that there
are other SIRT1 targeting miRNAs which were not investigated. In keeping with
such notion, in our array analysis, we noted that some SIRT1 targeting miRNAs
were downregulated (Table 3.1). Exact significance of such changes is not clear
and biological relevance remains to be established. Specific investigations are
required to establish whether such alterations may represent counter-regulatory
mechanism(s). Nevertheless, data from our study indicate that miR-195 may
represent a major miRNA, modulating SIRT1 activity in the context of early
diabetic retinopathy.
There are enormous evidences on the diverse role of miRNAs in various
physiological and pathological conditions; and have been associated in many
cellular processes including feedback loops for various signal transduction
pathways [27-34]. Interestingly, in a model of tumour angiogenesis, miR-195 has
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been shown to be decreased causing upregulation of VEGF [50]. Hence, it
appears that molecular mechanisms regarding miRNAs regarding VEGF
regulation may vary from tumoral to non-tumoral angiogenesis. It is also possible
that in diabetic retinopathy, additional mechanisms such as miR-195 mediated
reduced SIRT1 causing increased p300 and histone acetylation may lead to
increased VEGF production [10, 26]. Hence a complex interaction of miRNAs
and other epigenetic mechanism, such as histone acetylation may be involved in
specific protein production. Other miRNAs, eg. miR200b has also been shown to
regulate VEGF in diabetic retinopathy [42]. Nevertheless, as deregulation of
miRNAs lead to a variety of diseases, miRNAs have the potential to be used as
drugs. RNA based therapies are potentially advantageous due to their specificity.
Therefore, targeting few miRNAs in combinational therapy holds the potential to
prevent multiple gene expressions in a multifaceted disease like diabetic
retinopathy.
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Chapter 4

4

SIRT1 causes renal and retinal injury in diabetes
through endothelin 1 (ET-1) and transforming
growth factor beta 1 (TGF-β1)

Rokhsana Mortuza, Biao Feng and Subrata Chakrabarti.Department of
Pathology, Schulich School of Medicine & Dentistry,

University of Western

Ontario, London ON Canada.

In this study our aim was to investigate the effect of SIRT1 overexpression
in the organ damage in diabetic animals. We examined SIRT1 mediated
regulation of ET-1 and TGF-β1 in the renal and retinal tissues of the transgenic
mice with diabetes.
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4.1

Introduction

Diabetes and its complications are a growing concern worldwide [1].
Number of people being diagnosed with diabetes in North America is increasing
in an alarming rate [1]. Dysfunction of vascular endothelium caused by
hyperglycemia in diabetes is the key initiating factor in the development of all
chronic diabetic complications including diabetic nephropathy and retinopathy [2,
3]. A structural hallmark of chronic diabetic complication is vascular basement
membrane thickening and renal mesangial expansion, due to an increased
production of extracellular matrix (ECM) proteins such as fibronectin (FN) and
collagen. Although other cells may take part in such process, endothelial cells
(ECs) lining the blood vessels play a major role [2-5].
In diabetes glucose-induced increased oxidative stress activates several
signaling pathways altering crucial gene expressions in the ECs [6, 7]. We and
others have previously shown that endothelin-1 (ET-1) and transforming growth
factor β1 (TGF-β1) are increased in circulation of patients and in organs of the
animals with diabetes [2, 8-14]. ET-1 is a potent mitogen and vasoconstrictor that
plays a major pathogenic role in diabetic complications by altering the blood flow,
increasing vascular permeability and ECM protein production [8-13]. TGF-β1 is a
cytokine belonging to a large family of regulatory proteins and in recent years has
been evolved as one vital regulator of ECM protein production in diabetes [2, 8-
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14]. Increased TGF-β1 alters ECM protein synthesis and degradation, a delicate
balance that is lost in diabetes causing fibrosis in the affected tissues [2, 14]. We
have previously shown that diabetes-induced upregulated ET-1 and TGF-β1
levels causes increase production of ECM proteins in ECs and tissues of diabetic
animals [2, 8-14]. Moreover, we have demonstrated transcriptional co-activator
and histone acetyl transferase (HAT) p300 interacts with transcription factors
NFκB and AP-1 to regulate the expression of these genes [15-19].
SIRTs (silent information regulator proteins) are a group of NAD
dependent class III histone deacetylases (HDACs) that regulate epigenetic gene
silencing. SIRTs deacetylase not only histones but also many proteins and
transcription factors. SIRT1 is the leading enzyme in the SIRT family residing
both in the cytoplasm and nucleus. SIRT1 has been found to play crucial role in
cellular oxidative stress response, metabolism, differentiation, longevity and
various diseases including diabetes [20-23]. SIRT1 being a deacetylase also has
a regulatory relationship with p300 [20].
We investigated the role of SIRT1 and its relationship with p300 in
regulating ET-1 and TGF-β1 and their possible downstream consequences in
ECs and tissues of animals affected by diabetes. To this extent, we used human
microvascular ECs (HMECs) for in vitro inspections of glucose-induced
endothelial

alterations.

We

further

expanded

the

study

using

SIRT1

overexpressing transgenic mice in which we induced diabetes with streptozotocin
(STZ) and examined their renal and retinal tissues.
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4.2

Materials and methods

4.2.1 Cell culture

Dermal-derived human microvascular endothelial cell (HMEC) was
obtained (Lonza, Walkersville, MD) and grown in endothelial cell basal medium 2
(EBM-2, Lonza, Walkersville, MD). Human embryonic kidney (HEK293A) cells
were obtained from ATCC (Manassas, VA). We have previously described the
culture conditions of these cells [24-27]. The glucose concentration in the growth
medium was 5 mmol/L. No insulin was present in any media. All cells were
maintained in a humidified atmosphere containing 5% CO2 and at 370C
incubation. Cells were treated with normal glucose (NG, 5 mmol/L) or high
glucose (HG, 25 mmol/L D-glucose) or osmotic control (OSM, 25 mmol/L Lglucose). All reagents were obtained from Sigma Chemicals (Sigma, Oakville,
ON) unless specified otherwise. Experiments were conducted with 6-10
biological replicates.

4.2.2 Animal experiments

SIRT1 transgenic mice (C57BL/6-Actbtm3.1(Sirt1)Npa/J), male, 8 weeks old
were obtained (Jackson Laboratory, Bar Harbor, ME) and genotyped with Real
Time RT-PCR. Diabetes was induced by single intra-peritoneal injection of
streptozotocin (STZ, 65 mg/kg in citrate buffer). Age and sex matched mice were
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used as controls and received equal volume of citrate buffer. Diabetes was
defined in the animals with blood glucose level >20mmol/L on two consecutive
days (Abbott Diabetes Care, Saint-Laurent, QC). The animals were fed on a
standard rodent diet with water ad libitum and sacrificed after 2 months following
the development of diabetes (n = 10/group). Urinary micro-albumin (Exocell,
Philadelphia, PA) was measured as per the kit instructions. Retina and kidney
tissues were collected and snap frozen in liquid nitrogen for histology. All tissues
were stored at −80°C until further analysis.
All animal experiments were performed in accordance with regulations
specified by the Canadian Council of Animal Care. All protocols were approved
by the University of Western Ontario Animal Care and Veterinary Service. The
investigation was in compliance with the Guide for the Care and Use of Laboratory
Animals (NIH publ. no. 85-23, revised 1996).

4.2.3 SIRT1 enzyme activity assay

Whole cell lysate were collected following treatment with RIPA buffer
(Millipore, MA) with addition of protease inhibitor (Roche, Laval, QC). The total
protein concentrations of the samples measured using a commercially available
BCA protein assay kit (Pierce, Rockford, IL).Enzyme assay for SIRT1 activity
was performed as per the manufacturer instructions (Sigma, Oakville, ON). The
assay procedure is based on a two-step enzymatic reaction. In the first step
SIRT1 deacetylates the substrate that contains an acetylated lysine side chain. In
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the following step the deacetylated substrate is cleaved by the developing
solution and a highly fluorescent group is released. This measured fluorescence
is directly proportional to the deacetylation activity of the enzyme of the sample.
In short 35 µl of assay buffer was added to each well following which 10 µl of
sample and 5 µl of NAD+ was added. Adding to that 10 µl of SIRT1 substrate
solution was added and incubated at 37oC for 30 minute. Following this 5 µl of
developing solution was added and plate was incubated at 37oC for 10 minute.
The plates were read with a fluorescent spectrophotometer (Biotek, Winooski,
VT) at excitation 340 nm and emission 430 nm.

4.2.4 mRNA extraction and cDNA synthesis

RNA from cells was isolated using TRIZOL™ (Invitrogen, Burlington, ON)
reagent as established at our laboratory. Briefly RNA was extracted with
chloroform followed by centrifugation to separate the sample into aqueous and
organic phases. The RNA was recovered from the aqueous phase by isopropyl
alcohol precipitation and suspended in DEPC water. RNA concentration was
assessed on a spectrophotometer (Gene Quant-Pharmacia Biotech, Cambridge,
MA). First-strand cDNA was made by using High Capacity cDNA Reverse
Transcription kit (Applied Biosystems, Foster City, CA) according to the
manufacturer instruction. The resulting products were stored at −20°C until
further analysis by Real Time RT-PCR.
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4.2.5 mRNA analysis with Real Time RT-PCR

Real time RT-PCR was performed in LightCycler™ (Roche Diagnostics,
Laval, QC) to quantify the mRNA expression of SIRT1 and using the Qiagen One
Step RTPCR kit (detection platform SYBR Green I). All of the primers were either
ordered or custom made from Sigma (Table 4.1). For a final reaction volume of
20 µl, the following reagents were added: 4.4 µl of H2O, 10 µl of SYBR (Sigma,
Oakville, ON), 1.6 µl of MgCl2, 1 µl forward/reverse primer and 2 µl of cDNA. To
optimize the amplification of the genes, melting curve analysis (MCA) was used
to determine the melting temperature (Tm) of specific products and primer dimers.
According to the Tm value of specific products for respective genes, an additional
step (signal acquisition step, 2–3 °C below Tm) was added following the
elongation phase of RT-PCR. The data were normalized to housekeeping gene
18sRNA to account for differences in reverse transcription efficiencies and the
amount of template in the reaction mixtures.
Table 4.1 Oligonucleotide sequences for Real Time RT-PCR.
Name of Primer
Collagen Iα(I) (human)
ET-1 (human)
ET-1 (mice)
SIRT1 (human/mice)
P300 (human)
P300 (mice)

Sequence (5’ to 3’)
GAGGGCCAAGACGAAGACATC
CAGATCACGTCATCGCACAAC
AAGCCCTCCAGAGAGCGTTAT
CGAAGGTCTGTCACCAATGT
6FAM-TGACCCACAACCGAG-GBNFQ
TTAGCAAGACCATCTGTGTG
GAGTTTCTCCCTGAAATGTG
GCAGATTAGTAGGCGGCTTG
TCTGGCATGTCCCACTATCA
GGGACTAACCAATGGTGGTG
ATTGGGAGAAGTCAAGCCTG
AGGCAGAGTAGGACAGTGAA
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TGF-β1 (human)

TGF-β1 (mice)
18s (human/mice)

CTCAGTCTGGGTCACTCAAT
GCCCACTGCTCCTGTGACA
CGGTAGTGAACCCGTTGATGT
6FAM-CAGGGATAACACACTGC-MGBNFQ
TGGAGCAACATGTGGAACTC
GTCAGCAGCCGGTTACCA
GTAACCCGTTGAACCCCATT
CCATCCAACGGTAGTAGCG

′

4.2.6 Adenoviral overexpression of SIRT1 and SIRT1 gene silencing

SIRT1 adenovirus was obtained (ABM, Richmond, BC) and amplified in
HEK293A cells. HMECs were transfected with the adenovirus as described
earlier [24]. To silence SIRT1, transfection of small interfering RNA (siRNA) was
performed using N-TER nanoparticle siRNA transfection system (Sigma,
Oakville, ON) as described previously [20, 27]. Transfection efficiency was
assessed by Real Time RT-PCR.

4.2.7 p300 gene silencing and p300 overexpression

siRNA was used to specifically silence the p300 expression in ECs as
described by us previously [20]. P300 overexpression was achieved with
expression vectors (generously provided by Dr. Joan Boyes, The Institute of
Cancer Research, London, UK) containing the wild-type p300 (pCI-p300) and its
HAT-deletion mutant (pCI-p300 HAT∆1472–1522) as described earlier [15].
Transfection efficiency was assessed by measuring p300 mRNA expression by
Real Time RT-PCR.
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4.2.8 ET-1, TGF-β1 & FN ELISA

ET-1 ELISA (Enzo, Farmingdale, NY) and TGF-β1 ELISA (eBioscience,
San Diego, CA) was done on cell and tissue lysate as per the manufacturer
instructions. FN ELISA (abcam, Toronto, ON) was done on tissue lysate as per
the manufacturer instructions. The total protein concentrations were measured by
BCA protein assay kit (Pierce, Rockford, IL). The plate was read at 450 nm using
a plate reader (Multiskan, Thermofisher, Toronto, ON).

4.2.9 Total ROS/RNS assay

Total ROS/RNS (reactive oxygen species/reactive nitrogen species) assay
(Cell Biolab, San Diego, CA) on tissue lysate was measured as per the
manufacturer instructions. The plates were read with a fluorescent plate reader
(Biotek, Winooski, VT) at excitation 480 nm and emission 530 nm.

4.2.10 Endothelial permeability assay

HMECs were seeded onto inserts (1-mm pores) in 24-well plates, with or
without incubation with specific reagents for 24 h, and were tested for vascular
permeability using the In Vitro Vascular Permeability Assay Kit (Millipore,
Billerica, MA) according to the manufacturer’s instructions.

4.2.11 Western blotting
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The western blot analysis was conducted according to the standard
protocol established at our lab [15] using acetylated H3 lysine (Epigentek,
Farmingdale, NY) & β-actin antibody (Santa Cruz Biotechnology, Santa Cruz,
CA).

4.2.12 Statistical analysis

Data are expressed as mean ± SEM, normalized to controls. The
statistical significance of the results was analyzed by one way or two way
ANOVA followed by Tukey’s HSD post hoc correction and the two tailed Students
t test as appropriate (PASW Statistics 18, IBM, Canada). A p value < 0.05 was
considered statistically significant.

4.3

Results

4.3.1 SIRT1 regulates ET-1 and TGF-β1 expressions in the ECs in
high glucose.
As microvascular ECs are the major target of glucose-induced organ
damage, we investigated HMECs exposed to 5 (NG) and 25 (HG) mmol/L
glucose for 72 hrs. These concentrations are based on our previous dose
dependent analysis of SIRT1 levels [20, 24]. Quantitative Real Time RT-PCR
analysis of the ECs showed significant upregulation of ET-1 and TGF-β1 mRNA
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levels (Figure 4.1A,C) and downregulation of SIRT1 mRNA levels (Figure 4.1E)
with HG compared to NG. No effects were seen following incubation with osmotic
control (25mmol/L of L-glucose, OSM) (Figure 4.1A,C,E). These findings were
further reflected in ET-1 and TGF-β1 protein analysis and SIRT1 enzyme activity
analysis, which showed a marked increase of ET-1 and TGF-β1 protein levels
(Figure 4.1B,D) and reduced SIRT1 enzyme activity levels (Figure 4.1F) in these
cells following HG treatment (compared to NG).

Figure 4.1 SIRT1 regulates ET-1 and TGF-β1 expression in ECs. Human
Microvascular Endothelial cells (HMECs) exposed to 25 mmol/L (HG) glucose
compared to 5 mmol/L glucose (NG) showed increased (A) ET-1 mRNA, (C)
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TGF-β1 mRNA and reduced (E) SIRT1 mRNA expressions. Such changes were
not seen when the cells were incubated with 25 mmol L-glucose (osmotic control,
OSM). Transfection of endothelial cells with Ad-SIRT1 (but not the null vector)
increased (F) the enzyme activity in treated cells and normalized glucoseinduced upregulation of (A, C) ET-1 and TGF-β1 mRNA and

(B, D) protein

levels. Glucose-like effects (ET-1, TGF-β1upregulation) were further seen when
cells in NG were transfected with SIRT1 siRNA (A, C, E) but not with scramble
siRNA. Such knockdown of SIRT1 significantly reduced (F) the enzyme activity in
NG and increased the (B) ET-1 and (D) TGF-β1 protein levels in these cells. (*=
significantly different from NG, ǂ= significantly different from HG, mRNA levels
are expressed as a ratio of 18s. All data were normalized to NG).

We then proceeded to explore any relationship, between the observed glucoseinduced downregulation of SIRT1 and upregulation of ET-1 and TGF-β1
expressions in these ECs. For this purpose, we analysed the ECs following
transfection with SIRT1 adenovirus (Ad-SIRT1). Transfection efficiency was
measured with Real Time RT-PCR and confirmed with SIRT1 enzyme analysis
(Figure 4.1E,F). We noted the Ad-SIRT1 transfection significantly increased the
SIRT1 mRNA and enzyme levels in the ECs in HG (Figure 4.1E,F). Most
importantly, this transfection caused a significant reduction in ET-1 and TGF-β1
mRNA and protein levels in these ECs in HG (Figure 4.1A-D). ECs transfected
with null vector did not show such change (Figure 4.1A,C).
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In addition, SIRT1 knockdown with siRNA (efficiency in Figure 4.1E,F) in NG
mimicked the effects of HG, causing an increase in ET-1 and TGF-β1 levels in
these ECs (Figure 4.1A-D). Conversely, ECs transduced with scramble siRNA
did not show these changes (Figure 4.1A-D). These results demonstrated a
SIRT1 mediated regulation of ET-1 and TGF-β1 in the ECs in hyperglycemia.

4.3.2 SIRT1 regulates ET-1 and TGF-β1 expressions via p300.
In order to investigate the mechanism of such SIRT1 mediated ET-1 and
TGF-β1 regulation we looked at transcriptional co-activator p300, as we
previously have found SIRT1 and p300 balance each other [20]. In keeping with
the earlier findings we noted SIRT1 overexpression with adenovirus in 25 mmol/L
glucose normalizes glucose-induced augmented p300 mRNA levels (Figure
4.2A). On the contrary, SIRT1 knockdown in NG with siRNA caused an increase
in p300 mRNA levels (Figure 4.2A). Furthermore, p300 overexpression in these
cells in NG reduced the SIRT1 mRNA levels (Figure 4.2B,C). These changes
were not seen with null vector, scramble siRNA and p300 mutant transfections.
These results re-established a regulatory and balancing role of SIRT1 and p300
on each other in ECs.
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Figure 4.2 SIRT1 regulates ET-1 and TGF-β1 via p300. HG caused increased (A)
p300 mRNA and reduced (B) SIRT1 mRNA levels in ECs. (A) Ad-SIRT1
transfection in HG prevented p300 upregulation and SIRT1 knockdown with
siRNA in NG upregulated p300 mRNA levels. (B) p300 siRNA transfection in HG
(efficiency in A) normalized SIRT1 expression. Furthermore p300 overexpression
in NG (efficiency in A) reduced SIRT1 mRNA levels. (C, D) HG induced ET-1 and
TGF-β1 upregulation was abrogated with p300 siRNA (not with scramble)
transfection. p300 overexpression in NG upregulated the expressions of these
transcripts. (E, F) Rescue experiment showing upregulation of ET-1 and TGF-β1
mRNA levels in NG with SIRT1 knockdown can be resolved with subsequent
p300 knockdown in the ECs. (NG= 5 mmol/L glucose, HG= 25 mmol/L glucose,
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OSM = osmotic control, *= significantly different from NG, ǂ= significantly
different from HG, mRNA levels are expressed as a ratio of 18s. All data were
normalized to NG).

To confirm the downstream effects of such changes we examined the cells
following knockdown of p300 with siRNA (efficiency in Figure 4.2B) in HG. Such
treatment not only normalized the SIRT1 mRNA levels (Figure 4.2C) but also
reduced the ET-1 and TGF-β1 mRNA levels in HG (Figure 4.2D,E) compared to
scrambled controls. In addition, p300 overexpression in NG lead to an increased
mRNA levels for both ET-1 and TGF-β1 mimicking the HG treatments (Figure
4.2D,E). P300 mutant transfected cells did not show such change. These results
further establish that SIRT1 regulates ET-1 and TGF-β1 through p300.
We further conducted a rescue experiment to confirm such pathway. We first
knocked down SIRT1 with siRNA in NG in these ECs, following which we
transfected the cells with p300 siRNA. Transfection efficiency assessed with Real
Time RT-PCR showed reduction of both SIRT1 (88%) and p300 (61%) mRNA
levels in the treated cells. We noted such transfection prevented the ET-1 and
TGF-β1 mRNA upregulation in the treated cells (Figure 4.2F).
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4.3.4 SIRT1 overexpression prevent glucose-induced increased
endothelial permeability and collagen Iα(I) expression.
To investigate the functional consequences of SIRT1 mediated ET-1 and
TGF-β1 regulation we conducted trans-endothelial permeability assay as
increased endothelial permeability is a characteristic alteration in early diabetic
microangiopathy. Data from the In vitro permeability test showed HG significantly
increases ECs permeability and Ad-SIRT1 transfection prevented such leakage
in these cells (Figure 4.3A,B). P300 siRNA transfection in HG also had similar
effect showing reduction in glucose-induced leakage whereas; SIRT1 knockdown
or p300 overexpression in NG both significantly increased the ECs permeability
mimicking the HG (Figure 4.3A,B).
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Figure

4.3

SIRT1

overexpression

prevents

glucose-induced

increased

endothelial permeability and collagen Iα(I) expression. A) Duration dependent
endothelial permeability and (B) end point analysis showed, HG induced
increased endothelial permeability was prevented by Ad-SIRT1 transfection or
p300 siRNA treatment. SIRT1 siRNA or p300 overexpression in NG caused
increased permeability by these cells mimicking the effects of HG. (C) HG
caused an increase in Collagen Iα(I) mRNA expression in the ECs which was
prevented by Ad-SIRT1 or p300 siRNA transfection. Opposingly, SIRT1
knockdown or p300 overexpression both lead to an upregulation of Collagen Iα(I)
mRNA levels in NG. (D) Western blot analysis of acetylated histone (AcH3K9/14) shows Ad-SIRT1 or p300 siRNA transfection reduced HG-induced
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increased histone acetylation in HMECs. On the other hand SIRT1 siRNA or
p300 overexpression increased such acetylation in NG in these ECs. (NG= 5
mmol/L glucose, HG= 25 mmol/L glucose, *= significantly different from NG, ǂ=
significantly different from HG. HMECs= human microvascular endothelial cells.
mRNA levels are expressed as a ratio of 18s. All data were normalized to NG).

Previously we have shown SIRT1 overexpression prevented glucose-induced FN
upregulation in the ECs [27]. We further examined collagen Iα(I) expression
levels following HG exposure. With Ad-SIRT1 transfection, we observed a
normalization of glucose-induced upregulation of collagen Iα(I) mRNA levels
(Figure 4.3C).

HG induced increased collagen Iα(I) mRNA expression was

further prevented by p300 siRNA transfection (Figure 4.3C). In parallel, SIRT1
knockdown or p300 forced expression both caused an upregulation of collagen
Iα(I) mRNA levels in NG (Figure 4.3C). Moreover, we conducted western blot
analysis of acetylated histone (Ac-H3K9/14) to see the functional consequences
of p300 and SIRT1 alteration. Such analysis showed HG-induced increased AcH3K9/14 was reduced with Ad-SIRT1 or p300 siRNA transfection (Figure 4.3D).
Opposingly, SIRT1 siRNA or p300 forced expression in NG increased such
acetylation in the ECs. These experiments together provide further evidence that
SIRT1 regulate ET-1 and TGF-β1 through p300.
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4.3.5 SIRT1 regulate ET-1 and TGF-β1expressions in the kidney and
retina of diabetic mice.
Following the establishment that SIRT1 regulated ET-1 and TGF-β1 in
ECs, we expanded our study to investigate whether the mechanisms seen in
these

cells

was

important

in

the

development

of

renal

and

retinal

microangiopathy in a well-established animal model. STZ- induced diabetic mice
showed hyperglycemia (diabetics 21.91±4.58 mmol/L vs controls 7.38±0.91
mmol/L, P<0.001) and reduced body weight (diabetics 22.80±1.40 g. vs controls
30.25±2.36 g., P<0.001). Initially we performed Real Time RT-PCR analysis of
the renal and retinal tissue from these mice following 2 months of uncontrolled
diabetes. We have previously shown that diabetes induced increased ECM
protein and vasoactive factor expression is established at this time point [19, 20,
24-27]. mRNA analysis showed diabetic mice had significant downregulation of
SIRT1 expressions in the kidneys and retinas (Figure 4.4A,B). This finding was
further reflected in the SIRT1 enzyme activity levels (Figure 4.4C,D). Moreover,
these mice showed significant upregulation of p300 mRNA levels in the renal and
retinal tissues which were abrogated in SIRT1 overexpressing diabetic mice
(Figure 4.4E,F). Western blot analysis further showed SIRT1 overexpression
caused reduction in histone acetylation (Ac-H3K9/14) in these tissues
demonstrating the downstream functional consequences of p300 alteration in
these tissues (Figure 4.4G).
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Figure 4.4 SIRT1 overexpressing diabetic mice shows reduced p300 expressions
in the kidney and retina. Transgenic mice with SIRT1 overexpression (SIRT1 Tg)
showed increased expressions of (A, B) SIRT1 mRNA levels and (C, D) enzyme
activity in the kidneys and retinas of diabetic and control animals.

Such

overexpression averted diabetes-induced increased (E, F) p300 mRNA levels
and (G) histone acetylation (Ac-H3K9/14) in these tissues. (Co= Control,
Di=Diabetic, *= significantly different from control, ǂ= significantly different from
Diabetic. mRNA levels are expressed as a ratio of 18s. All data were normalized
to Co).
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We further looked at ET-1 and TGF-β1 levels in these mice. SIRT1
overexpressing diabetic mice showed significantly reduced level of ET-1 and
TGF-β1 mRNA levels compared to diabetic mice in both tissues (Figure 4.5A-D).
We further confirmed these results using ELISA which showed diabetes-induced
increased ET-1 and TGF-β1 protein levels in the renal and retinal tissues are
significantly reduced with SIRT1 overexpression in these tissues (Figure 4.5E-H).

Figure 4.5 SIRT1 regulates ET-1 and TGF-β1 expressions in kidney and retina of
diabetic mice. SIRT1 overexpression was protective against diabetes-induced (A,
B) ET-1 and (B, C) TGF-β1 mRNA upregulation in the kidneys and retinas of
mice. In keeping with the mRNA expressions SIRT1 transgenic mice (SIRT1 Tg)
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with diabetes showed reduced (E, F) ET-1 and (G, H) TGF-β1 protein levels in
these tissues compared to the wild type diabetic mice. (Co= Control, Di=
Diabetic, *= significantly different from control, ǂ= significantly different from
Diabetic. mRNA levels are expressed as a ratio of 18s. All data were normalized
to Co).

4.3.6 SIRT1 overexpression prevents diabetes-induced microalbuminuria and FN upregulation in tissues.
To examine the downstream consequence of SIRT1 mediated alteration of
ET-1 and TGF-β1 in diabetes, we investigated urinary micro-albumin levels to
assess renal function in these mice. Diabetic mice showed increased microalbuminuria compared to controls indicating poor kidney function in these
animals (Figure 4.6A). SIRT1 overexpression significantly reduced microalbuminuria and diabetes-induced increased collagen Iα(I) mRNA expression by
the transgenic diabetic animals (Figure 4.6A,B). Furthermore in the renal and
retinal tissues of the diabetic animals such overexpression reduced diabetesinduced increased FN protein and total ROS/RNS levels (Figure 4.6C,D). These
results suggest that SIRT1 has a protective role against diabetes-induced renal
and retinal damages.
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Figure 4.6 SIRT1 transgenic mice shows improved renal function and reduced
oxidative stress and FN upregulation with diabetes. (A) SIRT1 overexpression
prevented diabetes-induced micro-albuminuria in mice. Furthermore such
overexpression averted diabetes-induced increased (B) collagen Iα(I) mRNA
expression (C) FN protein and (D) total ROS/RNS levels in the renal and retinal
tissues. (SIRT1 Tg= SIRT1 transgenic mice, Co= Control, Di= Diabetic, *=
significantly different from control, ǂ= significantly different from Diabetic. mRNA
levels are expressed as a ratio of 18s. All data were normalized to Co).
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4.4

Discussion
In this study we have shown that SIRT1 regulates glucose induced

overexpression of ET-1 and TGF-β1 in the ECs. We have also shown that SIRT1
regulates ET-1 and TGF-β1 levels in the kidneys and retinas of diabetic animals.
In addition we have demonstrated such processes are regulated through
transcriptional co-activator p300. Using adenoviral overexpression of SIRT1 and
knockdown of SIRT1 with siRNA, we have directly demonstrated that glucoseinduced ET-1 and TGF-β1 upregulation can be markedly reduced by increasing
the availability of SIRT1. In the kidneys and retinas of SIRT1 overexpressing
transgenic mice we have further established the existence of such regulation in a
STZ- induced type 1 model of diabetes. To be best of our knowledge, such
SIRT1 mediated regulation of ET-1 and TGF- β1 in diabetic complications have
not been shown earlier.
In diabetes, high oxidative stress due to hyperglycemia causes DNA
damage and activates several transcription and vasoactive factors altering crucial
gene expressions [2, 6, 7]. Here we describe the role of SIRT1 causing
protection

against

ET-1

and

TGF-β1

induced

endothelial

damage

in

hyperglycemia. We initially demonstrated SIRT1 downregulation in parallel to ET1 and TGF-β1 upregulation in glucose exposed ECs. Then, we directly
demonstrated its functional significance in terms of endothelial permeability and
collagen Iα(I) expression and the relationship with p300 in these cells. In keeping
with our earlier findings here we have shown that acting in opposing manner,
p300 and SIRT1 regulate each other in hyperglycemia. We further showed the
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functional significance of this mechanism in an animal model of diabetic
microangiopathy.
Although there is no previous work showing SIRT1 mediated regulation of
ET-1 or TGF-β1 expressions, SIRT1 has been found to regulate downstream
effectors of TGF-β1 via deacetylation of SMAD7 [28]. This study demonstrates a
SIRT1 mediated regulation of TGF-β1 expressions which signals through
SMADs. One of the major glucose-induced endothelial dysfunctions includes
augmented ECM protein production [2-14]. Increased ECM proteins are
deposited in the tissue which is manifested as structural changes such as
basement membrane thickening, mesangial expansion etc. We and others have
demonstrated glucose-induced increased collagen and FN synthesis in the
endothelial cells and in the retina, kidney and heart in diabetes [2-19]. We have
also demonstrated that glucose induced ECM protein upregulation is mediated
through p300-dependent histone acetylation and p300 binds to the promoter
regions of ET-1 and FN genes [15-19]. In this study we have shown one further
step of p300 mediated regulation of ET-1 and TGF-β1 in ECs and tissues of
diabetic animals. We have shown that by modulating SIRT1 we can prevent such
glucose induced damages.
ET-1 and TGF-β1 are two important cytokines playing key roles in tissue
damage in diabetic complications. It is of interest to note that such SIRT1
induced regulation is mediated through p300. P300 as a transcriptional coactivator is potentially capable of altering multiple transcripts [15, 18, 19]. This
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study shows it is possible to target either SIRT1 or p300 to prevent diabetesinduced alterations. We have previously shown that p300 is regulated by miR200b and it regulates miR-146a [24, 26]. Additionally we have shown that miR195 regulates SIRT1 expression [27]. In this assumption we showed a ying-yang
relationship between p300 and SIRT1. Hence a complex web connecting multiple
such epigenetic processes involving acetylators, deacetylators, miRNAs and
other undetermined epigenetic process may ultimately dictate expression of
specific transcripts. It is also possible that SIRT1 may influence several other
inflammatory cytokines which are of importance in the context of nephropathy
and retinopathy and other chronic diabetic complications. However, such roles of
SIRT1 in these processes need to be established in future through specific
experiments.
The pathogenic mechanisms leading to chronic diabetic complications are
complex. Several vasoactive and growth factors are simultaneously activated in
response to hyperglycemia and an intricate interplay occurs among such factors
[2-20, 24-26]. The findings of this study indicate that SIRT1 is a protective
molecule in diabetic nephropathy and retinopathy. Loss of SIRT1 production
represents a key event in the pathogenesis of chronic diabetic complications.
Hence SIRT1 holds the potential to be used as a drug target for the treatment of
chronic diabetic complications.
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5.1

Overall findings

The major contributor of vascular diabetic complications is damage to the
ECs [1-22]. Hyperglycemia induced increased oxidative stress causes ECs to
secrete large amount of vasoactive factors, growth factors and cytokines [1-22].
These factors lead to structural and functional changes in the ECs such as
increased permeability and basement membrane thickening [1-22]. We and
others have previously shown that glucose-induced increased oxidative stress
alters expression of several genes ultimately causing increased production of
ECM proteins by the ECs such as collagen and FN [1-22]. Interestingly some of
these above mentioned changes are also seen in normal vascular aging [23-37].
Hence in this study we asked whether hyperglycemia in diabetes accelerates
aging-like process in ECs and tissues of diabetic animals (chapter 2).
To create an aging-like in vitro process, we continuously propagated ECs
of three different origins (HMEC, BREC and HUVEC) in high and normal glucose
and examined for signs of cellular senescence and oxidative stress. We found
oxidative stress in hyperglycemia accelerated aging-like changes in ECs.
However such processes were variable among the various ECs. Microvascular
ECs were more susceptible to glucose induced rapid aging compared to large
vessel ECs. As we looked into the mechanism behind such aging process we
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found SIRT enzymes were reduced in the aged cells. Glucose-induced increased
oxidative stress caused reduction of mitochondrial antioxidant enzymes in a
SIRT1 and FOXO1 mediated pathway. Moreover level of SIRT1 was negatively
regulated by p300, a HAT and transcriptional co-activator. Using activators of
SIRT1 we were able to effectively prevent such aging-like changes in the ECs. In
addition, examination of kidneys and retinas of diabetic mice showed that
diabetes causes rapid aging in these tissues. Such changes were associated
with increased oxidative stress and reduced SIRT1 enzyme levels. Overall

we

have found an important role played by SIRTs in such process. We showed an
important mechanistic pathway of oxidative stress and aging in HG, mediated
through FOXO1 and regulated by SIRT1 and p300 (chapter 2).
Next we investigated regulation of SIRT1, specially by miRNAs (chapter
3). miRNAs are post transcriptional regulators of genes. miRNAs are conserved
non-coding RNAs and are highly specific in nature, hence holds tremendous
potential to be used as therapeutic targets. Several miRNAs have been found to
regulate SIRT1 in various physiological and pathological conditions. In this study
we examined alteration of SIRT1 targeting miRNAs in the retinal tissues of
animals with diabetes.
Our initial microarray analysis showed miR-195, a SIRT1 targeting miRNA
was significantly overexpressed in the retinas of diabetic animals. We then
validated such findings in two different type of microvascular ECs. This was
associated with reduced SIRT1 levels in these cells. We then examined the
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possible miR-195 mediated regulation of SIRT1 at multiple levels of complexities
in the context of diabetic retinopathy.
We used miR-195 antagomir, mimic and adenovirus with SIRT1
overexpression to identify in vitro biological significance. We found miR-195
antagomir transfection significantly upregulated SIRT1 levels in the ECs. Such
transfection further prevented SIRT1 mediated aging changes and reduced
glucose-induced increased FN levels in the ECs. SIRT1 overexpression in high
glucose showed similar effect whereas miR-195 mimic transfection in NG
mimicked the high glucose effect. We also showed similar alterations and its
functional significance in an animal model of diabetic retinopathy. By injecting
miR-195 antagomir intravitreally in STZ induced type 1 diabetic rats, we showed
such treatment prevented SIRT1 reduction in these tissues following 1 month of
uncontrolled hyperglycemia. Such treatment also reduced diabetes induced
increased vascular permeability and normalized FN proteins levels. Overall in
this study we have shown a novel role of miR-195 regulating hyperglycemia
induced changes through SIRT1 in microvessels in diabetes. Data from this
study indicate that miR-195 may represent a major miRNA, modulating SIRT1
activity in the context of early diabetic microangiopathy.
In order to explore the role of SIRT1 further and to examine whether such
mechanisms are universal in other organs affected by diabetic complications, we
investigated transgenic mice with SIRT1 overexpression (chapter 4). We induced
diabetes in these mice with STZ injection and examined their kidney and retinal
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tissues, for possible alteration of genes which are major players of diabetic
microangiopathy. We found these transgenic mice had significantly reduced
levels of ET-1 and TGF-β1, two major factors of vascular pathogenesis, in the
renal and retinal tissues. This finding intrigued us to investigate a possible SIRT1
mediated regulation of ET-1 and TGF-β1 in diabetes.
Using adenoviral overexpression of SIRT1, we found that glucose-induced
ET-1 and TGF-β1 upregulation can be markedly reduced by increasing the
availability of SIRT1. Such treatment also corrected glucose-induced increased
endothelial permeability and increased FN, collagen expressions. Moreover we
found such SIRT1 mediated ET-1 and TGF-β1 regulation is mediated through
transcriptional co-activator p300. We further found similar relationships in the
SIRT1 transgenic mice with diabetes. These findings established that SIRT1 can
provide protection against ET-1 and TGF-β1 induced endothelial damage in
hyperglycemia. In keeping with our earlier findings we found again that p300 and
SIRT1 regulate each other in hyperglycemic conditions and by modulating any of
these we can prevent some glucose induced SIRT1 mediated damages.
Together the findings of this research show a novel role played by SIRT1 in
diabetic microangiopathy. Data from this study indicate that SIRT1 is a protective
molecule in diabetic vascular complications and holds the potential to be used as
a therapeutic target for the treatment of diabetes.
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5.2

Limitations and future directions
There is no study without limitations. In this study we have mainly focused

on SIRT1 mediated alterations in ECs and renal and retinal tissues in diabetes.
Whether similar changes occur in other organs affected by diabetes such as
brain, liver, heart etc were not examined and needs further investigation.
Furthermore, we have not looked in detail the role of other SIRTs (2-7) in
endothelial dysfunction. As mitochondrial oxidative stress is the root cause of
endothelial damage in diabetes, mitochondria specific SIRTs such as SIRT 3, 4,
5 may play key role in such process and needs further investigation.
The present study was performed on animals with type 1 diabetes. Future
studies need to be done to see the effect of SIRT1 alteration in type 2 and
gestational diabetes. In chapter 3 we examined the regulation of SIRT1 with miR195 in the context of diabetic retinopathy. We have seen miR-195 inhibitor has
some protective benefit in such disease process mediated through SIRT1. More
work is needed to examine if such beneficial effects are present in other target
organs of diabetic complications.
Although we have done several animal studies, a lot of our work is based
on cultured ECs. ECs in cultured in vitro conditions is much simpler an
environment than in vivo, which has more interaction between ECs, ECM
proteins and other cells (smooth muscle cells, immune cells, fibroblasts etc).
Furthermore though rodent models share a large percentage of their DNA with
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humans significant differences exist. These factors should be considered before
translating the current study to human.
Several SIRTs share molecular targets and affect common pathogenic
pathways. To what extent SIRTs possess unique versus redundant functions and
the degree to which crosstalk exists between these enzymes are some of the key
questions that need to be systematically investigated. Questions such as to what
extent activation of all SIRTs occur as a consequence of increased cellular NAD+
levels or whether different SIRTS have opposing roles in a disease condition
(such as cancer) need to be investigated. We further need to examine possible
consequences of long term increase in SIRT activity in vivo, before considering it
to be a viable therapy. Although overexpression of SIRTs in some specific
contexts have been found to confer health benefits and increase longevity, in
general it is unknown whether long-term sustained increase of SIRT activity may
have any deleterious consequences or not.
Finally although recently some studies investigating posttranslational
modifications

of

SIRTs

are

emerging,

further

mechanistic

studies

on

physiological regulation of SIRT needs to be done to gain insights into its function
and features so that it may be used as a specific drug target.
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Appendix-Experimental methods and materials

Cell culture
Bovine retinal microvascular endothelial cells (BRECs) were obtained from
VEC Technologies (Rensselaer, NY) and were grown in a defined endothelial cell
growth medium (MCDB-131 complete). The cells were passaged in 12 well plate
(Corning, Acton, MA) coated with fibronectin (Sigma, St. Louis, MO). Dermalderived human microvascular endothelial cell (HMEC) was obtained from Lonza,
Inc. (Walkersville, MD) and human retinal microvascular endothelial cells
(HRECs) were obtained from Olaf Pharmaceuticals (Worchester, MA). HRECs
and HMECs were grown in endothelial cell basal medium 2 (EBM-2, Lonza,
Walkersville, MD). Human umbilical vein endothelial cells (HUVECs) were
obtained from Clonetics (Rockville, MD, USA), were cultured in endothelial cell
growth medium (EGM). Human embryonic kidney (HEK293A) cells were
obtained from ATCC (Manassas, VA) and cultured as per the manufactures
protocol. The glucose concentration in the growth medium was 5 mmol/l. No
insulin was present in any media. All cells were maintained in a humidified
atmosphere containing 5% CO2 and at 370C incubation [1-7]. Reagents were
obtained from Sigma Chemicals (Sigma, Oakville, ON) unless specified
otherwise.
For the long term continuous exposure to glucose, ECs were cultured in
12 well plates (Corning, Acton, MA) and treated with 5mM glucose (NG) or 25mM
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glucose (HG, D-glucose) or osmotic control (OSM, 25 mM L-glucose). Upon
confluence cells were propagated & maintained in the same treatment condition
until they stopped proliferating completely. During each passage subculture cells
from each treatment group were stained for SA β-gal and collected for RNA
analysis. Cells were monitored daily and images taken for morpholocigal and
growth analysis. To test the effect of SIRT activation on accelerated aging in
diabetes, cells were treated with 10 µM resveratrol (Sigma, Oakville, ON)
dissolved in ethanol or with 25 µM BML278 (ENZO, Farmingdale, NY) in DMSO
for 72 hr. To investigate the effect of FOXO1 inhibition, cells were treated with
0.1 µM FOXO1 inhibitor AS1842856 (Millipore, Billerica, MA) in DMSO similarly
[3].
Cell lysates were collected with RIPA (Millipore, Billerica, MA) buffer with
protease inhibitor (Roche, Laval, QC) for total ROS/RNS, MnSOD, ET-1, TGFβ1, LDH, SIRT1 analysis. Total protein concentrations were measured by BCA
protein assay kit (Pierce, Rockford, IL). All experiments were conducted with 610 biological replicates [3].
Extraction of mRNA and cDNA synthesis
RNA from cells was isolated using TRIZOL™ (Invitrogen, Burlington, ON).
Then RNA was further extracted with chloroform followed by centrifugation to
separate the sample into aqueous and organic phases. The RNA was recovered
from the aqueous phase by isopropyl alcohol precipitation and suspended in
DEPC water. RNA concentration was assessed on a spectrophotometer (Gene
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Quant-Pharmacia Biotech, Cambridge, MA). First-strand cDNA was made by
using High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster
City, CA) as per the manufacturer instruction [1-7]. The resulting products were
stored at −20°C until further analysis by Real Time RT-PCR.

mRNA analysis with quantitative Real Time RT-PCR
Real time RT-PCR was performed in LightCycler™ (Roche Diagnostics,
Laval, QC) to quantify the mRNA expression of SIRT(1-7), hTERT, p300, FN,
ET-1, TGF-β1 and CollagenIα(I) using the Qiagen One Step RTPCR kit
(detection platform SYBR Green I). All of the primers were either ordered or
custom made from Sigma. For a final reaction volume of 20 µl, the following
reagents were added: 4.4 µl of H2O, 10 µl of SYBR (Sigma, Oakville, ON), 1.6 µl
of MgCl2, 1 µl forward/reverse primer and 2 µl of cDNA. To optimize the
amplification of the genes, melting curve analysis (MCA) was used to determine
the melting temperature (Tm) of specific products and primer dimers. According to
the Tm value of specific products for respective genes, an additional step (signal
acquisition step, 2–3 °C below Tm) was added following the elongation phase of
RT-PCR. The additional step in the PCR reactions is allowed for signal
acquisition from specific target products. The data were normalized to
housekeeping gene 18sRNA or β-Actin to account for differences in reverse
transcription efficiencies and the amount of template in the reaction mixtures [17].
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SIRT1 enzyme activity assay
Enzyme assay for SIRT1 activity was performed on cell lysate or tissue
homogenate as per the manufacturer instructions (Sigma, Oakville, ON). The
assay procedure is based on a two-step enzymatic reaction. In the first step
SIRT1 deacetylates the substrate that contains an acetylated lysine side chain. In
the following step the deacetylated substrate is cleaved by the developing
solution and a highly fluorescent group is released. This measured fluorescence
is directly proportional to the deacetylation activity of the enzyme of the sample.
In short 35 µl of assay buffer was added to each well following which 10 µl of
sample and 5 µl of NAD+ was added. Adding to that 10 µl of SIRT1 substrate
solution was added and incubated at 37oC for 30 minute. Following this 5 µl of
developing solution was added and plate was incubated at 37oC for 10 minute.
The plates were read with a fluorescent spectrophotometer (Biotek, Winooski,
VT) at excitation 340 nm and emission 430 nm [3, 8].
SIRT1 gene silencing
To silence SIRT1, transfection of small interfering RNA (siRNA) was performed
using N-TER nanoparticle siRNA transfection system (Sigma, Oakville, ON)
according to the manufacture’s protocol [1, 3, 9]. SIRT1 siRNA1 was purchased
from Dharmacon Inc. (Lafayette, CO) and SIRT1 siRNA2 was purchased from
Santa Cruz Biotecnology (Santa Cruz, CA). Cells were incubated with or without
glucose after transfection for 24 hr and sample collected for mRNA analysis. To
test the effect of SIRT1 siRNA on resveratrol, the siRNA was added 48 hr post
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treatment with resveratrol in the cultured cells and samples collected 24 hr post
transfection. The transfection efficiency was assessed by real-time RT-PCR.
p300 gene silencing and p300 overexpression
To silence the p300 expression in ECs, p300 siRNA1 (Silencer, Ambion, Austin,
TX) and p300 siRNA2 (Santa Cruz Biotechnology, Santa Cruz, CA) was used
with siPORT Lipid transfection reagent (Ambion, Carlbad, CA). ECs were
transfected with p300 siRNAs (100 ηmol/l) with the siRNA transfection reagent (1
µl/500 µl transfection volume). Cells were incubated with or without glucose for
24 hr following the transfection and collected for mRNA analysis [1, 3]. Some
transfected cells were further treated with glucose upto passage 1 and sample
collected for SA-βgal staining, nuclear fraction isolation and protein analysis.
siRNA transfection efficiency was indirectly assessed by measuring p300 mRNA
expression by real-time RT-PCR.
P300 overexpression was achieved with expression vectors (generously
provided by Dr. Joan Boyes, The Institute of Cancer Research, London, UK)
containing the wild-type p300 (pCI-p300) and its HAT-deletion mutant (pCI-p300
HAT∆1472–1522). The plasmids were transfected and amplified in DH5a
Escherichia coli bacteria following which extracted with the QIApre Spin Miniprep
Kit (Qiagen, Toronto, ON). HMECs were transfected with 2 µg/flask (T25) of
plasmids with Lipofectamine 2000 (Invitrogen, Burlington, ON, Canada)
according to the manufacturer’s instructions [1, 3]. Cells were incubated with or
without glucose for 24 hr following the transfection and collected for mRNA
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analysis. Some transfected cells were further treated with glucose upto passage
1 and sample collected for mRNA and protein analysis. Transfection efficiency
was assessed by measuring p300 mRNA expression by Real Time RT-PCR.
ET-1, TGF-β1 ELISA and Telomerase activity
ET-1 ELISA (Enzo, Farmingdale, NY) and TGF-β1 ELISA (eBioscience, San
Diego, CA) was done on cell and tissue lysate as per the manufacturer
instructions [2, 6, 10-13]. The total protein concentrations were measured by
BCA protein assay kit (Pierce, Rockford, IL). The plate was read at 450 nm using
a plate reader (Multiskan, Thermofisher, Toronto, ON). Telomerase activities of
the samples were measured using a commercially available kit following
instructions provided by the manufacturer (Allied Biotech Inc., Germantown, MD).

Endothelial permeability assay
To examine endothelial permeability, the In Vitro Vascular Permeability Assay Kit
(Millipore, Billerica, MA) was used according to the manufacturer’s instructions
[14]. HMECs were seeded onto collagen coated inserts (1mm pores) in 24-well
plates. Following the formation of cell monolayer (2-3 days), cells were treated
with specific reagents (Ad-SIRT1, p300 siRNA, p300 plasmid, SIRT1 siRNA) with
or without glucose for 72 h. After treatment FITC-Dextran is added to the cells
and permeability of this fluorescent molecule is measured at several intervals (30
minute, 1 hour, 1.5 hour and 2 hour). The plates were read with a fluorescent
spectrophotometer (Biotek, Winooski, VT) at excitation 485 nm and emission 535
nm.
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Western blot for protein analysis
Western blot analysis was conducted according to the standard protocol
established at our lab [1, 3] using SIRT1, p300, Ac-FOXO1, β-actin (Santa Cruz
Biotechnology, Santa Cruz, CA) and acetylated H3 lysine antibody (Epigentek,
Farmingdale, NY). About 200 µg of protein was extracted from each well/tissue.
20 µg per lane of cellular or nuclear protein was resolved by 5–10% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis. Signals were detected with
horseradish

peroxidase-conjugated

secondary

antibody

(Santa

Cruz

Biotechnology, Santa Cruz, CA) and developed with the chemiluminescent
substrate (Amersham Pharmacia Biotechnology, Piscataway, NJ) as per the
manufacturer instructions.

miRNA extraction and analysis
miRNAs were extracted from the cells and tissues using the mirVana miRNA
isolation kit (Ambion, Inc., Austin, TX). Briefly, the cells were collected and wash
2 times by using PBS.

The tissues were homogenized in the Lysis/Binding

solution and miRNA additive(1:10) was added to the samples on ice for 15
minutes. Equal volume acid-phenol: chloroform was added to cell suspension
and the tissue lysate, and mixed for 30 seconds by vortex. Following
centrifugation and removal of the aqueous phase, the mixture was added 1.25
fold 100% ethanol. The mixture was passed through the filter cartridge and
eluted with elution solution. The real-time PCR was used with a final reaction
volume of 20 µL containing 10 µL TaqMan 2X Universal PCR Master Mix (No
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AmpErase UNG), 1 µL TaqMan microRNA assay (Applied Biosystems Inc, CA,
USA), 8 µL Nuclease-free water and 1 µL RT-product. The data was normalized
to RNU6B snRNA to account for differences in reverse-transcription efficiencies
and amount of template in the reaction mixtures [14-16].

miRNA mimic or antagomir transfection
The HMECs and HRECs were transfected with miRIDIAN microRNA-195 mimic
or antagomir (20 nM) (Dharmacon Inc., Chicago, IL) using transfection reagent
Lipofectamine2000 (Invitrogen, Burlington, ON). miRIDIAN microRNA mimic or
antagomir scrambled control were used in parallel. Transfection efficiency of
miRNA was determined by real time RT-PCR [14-16].

Adenoviral forced-expression of SIRT1
SIRT1 adenovirus (devoid of 3’UTR) and null vector was obtained from ABM
(Richmond, BC, Canada) and amplified in HEK293A cells [16, 17]. HRECs &
HMECs were grown in standard 6-well plates to 90% confluence. Next, cells
were transfected with 1 ml Ad-SIRT1 or the empty vector. Subsequently, 3 mL of
additional media was added 4 h later and the transfected cells were incubated
with or without glucose for 72 h. Cells were either collected with RIPA buffer for
protein analysis or TRIZOLTM (Invitrogen, Burlington, ON) for RNA analysis.

Luciferase Reporter Assay for Targeting SIRT1-3'UTR
The luciferase vector including 3′UTR of SIRT1 (1080 bp) containing the SIRT1miR-195 response elements (wt-Luc-SIRT1) and the mutant (mu-Luc-SIRT1)
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were purchased from Norclone Biotech Laboratories (London, ON, Canada).
Plasmid DNA (wt-Luc-SIRT1 or mu-Luc-SIRT1, β-galactosidase control vector)
and miR-195 mimic or scrambled oligonucleotide were co-transfected in HRECs
for 48 hours. The luciferase activity was measured using the Dual-Light
Chemiluminescent

Reporter

Gene

Assay

System

(Applied

Biosystems,

Burlington, ON) and SpectraMax M5 (Molecular Devices, Sunnyvale, CA). The
luciferase activity was normalized for transfection efficiency by measuring the βgalactosidase activity according to the manufacturer’s instructions [14-16].
Animal Experiments
All animal experiments were conducted following guidelines specified by the
Canadian Council of Animal Care. Protocols were approved by the Western
University Animal Care and Veterinary Service. The investigations were in
accordance with NIH publ. no. 85-23, revised 1996.
Male C57BL/6 mice (20-25g), were obtained (Charles River, Wilmington,
MA) and diabetes was induced by 1-2 intraperitoneal injection of streptozotocin
(STZ) (65 mg/kg, in citrate buffer, pH 5.6). Age- and sex-matched mice were
used as controls and given equal volumes of citrate buffer. db/db (Leprdb, DBA/J)
mice (8 weeks, Jackson Laboratory, CA) were used as type 2 model of Diabetes.
The animals were monitored daily [3, 18-23]. The animals were killed at 2 & 4
months following the development of diabetes (n = 10/group). Retinal and renal
cortical tissues were dissected out and snap frozen in liquid nitrogen. All tissues
were stored at −80°C until further analysis. Urinary albumin (Exocell,
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Philadelphia, PA) and serum creatinine (Arbor assays, Ann Arbor, MI) were
measured as per the instructions.
Sprague-Dawley rats (~175g, 6 weeks, male) were obtained (Charles
River, Wilmington, MA) and diabetes was induced by a single intraperitoneal
injection of streptozotocin (STZ) (65 mg/kg, in citrate buffer, pH 5.6). Control
animals received equal volume of citrate buffer. Diabetes was determined as a
blood glucose level >20 mmol/l on 3 successive days (Abbott Diabetes Care,
Alameda, CA). Animals were fed on a standard diet with water ad libitum and
monitored daily [16, 18-23]. A group of diabetic rats (n=7/group) received weekly
intravitreal injections of 1.5 µg miR-195 mimic or antagomir in lipofectamine
reagent in one eye. The other eye received scrambled control. They were
sacrificed one week after the fourth injection. Retinal tissues were collected, snap
frozen and were stored at −80°C until further analysis. To assess intravitreal
miRNA penetration efficiency DY547 (red fluorescent dye) tagged miRNA
scramble transfection control (Dharmacon Inc., Chicago, IL) was injected
intravitreally and retinal tissues were collected from sacrificed animals at 2 hr,
4hr, 8hr and 24hr following injection and snap frozen [24]. Slides from the same
sections were counterstained with H&E for orientation.
SIRT1 transgenic mice (C57BL/6-Actbtm3.1(Sirt1)Npa/J), male, 8 weeks old
were obtained (Jackson Laboratory, Bar Harbor, ME) and genotyped with Real
Time RT-PCR. Diabetes was induced by 1-2 dose of intra-peritoneal injection of
streptozotocin (STZ, 65 mg/kg in citrate buffer). Age and sex matched mice were
used as controls and received equal volume of citrate buffer [3, 16, 18-23].
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Diabetes was defined in the animals with blood glucose level >20mmol/L on two
consecutive days (Abbott Diabetes Care, Saint-Laurent, QC). The animals were
fed on a standard rodent diet with water ad libitum and sacrificed after 2 months
following the development of diabetes (n = 10/group). Urinary micro-albumin
(Exocell, Philadelphia, PA) was measured as per the kit instructions. Retina and
kidney tissues were collected and snap frozen in liquid nitrogen for histology. All
tissues were stored at −80°C until further analysis.
In situ Hybridization & Immunohistochemistry
A 5' and 3' double DIG-labelled custom-made mercury LNA™ miRNA detection
probes (Exiqon, Vedbaek, Denmark) were used to detect miR-195 expression
using in situ hybridization(ISH) Kit (Biochain Institute, Hayward, CA) in retinal
tissue sections. Scrambled probe and no-probe were used as controls [14-16,
25]. IgG stainings were performed on frozen retinal sections using anti-rat IgG
(ebioscience,

Sandiego,

CA)

with

hematoxylin

counterstain

[14-16].

Quantification was done in a masked fashion using an arbitrary scale (0 = no
extravascular stain of retina, 1 = mild extravascular stain,

2 = moderate

extravascular stain, 3 = marked extravascular stain).

SA β-gal staining for senescence
Cells or frozen tissue sections were fixed and stained with SA β- gal staining
according to the manufacturer’s instructions (abcam, Cambridge, MA). In short,
cells or frozen tissue sections were washed with PBS and fixed with fixative
solution for 10-15 minutes at room temperature. Following two washes with PBS
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cells/slides were covered in staining solution and incubated overnight at 37oC.
For long-term storage of the stained plates/slides, the staining solution was
removed and overlaid with 70% glycerol and stored at 4oC. Tissue slides were
counterstained with H&E staining for orientation purpose [26].

Phase contrast and fluorescent microscopy
From each specimen, positive (blue) cells were photographed with phase
contrast inverted microscope using SPOT Basic software (Meiji Techno, TC5400,
Santa Clara, CA). Morphometrical analysis of the images was done by ImageJ
software (NIH, Bethesda, MD). They were counted per 10 microscopic fields at
20X magnification and presented as % of total number of cells.
Images of the tissue slides were recorded by an Olympus BX51
microscope (Olympus, Center Valley, PA) with Northern Eclipse software (Empix
Inc, Cheektowaga, NY).Tissue slides were quantified based on staining intensity
[27] at 60X magnification. Quantification of SA-β-Gal intensity was done in a
masked fashion using an arbitrary scale (0 = no stain, 1 = focal weak stain, 2 =
multifocal moderate stain,

3 = multifocal intense stain). Fluorescent

microscopies of frozen retinal sections were performed with TRITC filter at 20X
magnification.

Total ROS/RNS and Intracellular LDH analysis
Total ROS/RNS level in the EC lysates/tissue homogenates were measured as
per the manufacturer instructions using a commercially available kit (Cell Biolabs
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Inc., San Diego, CA). The plates were read with a fluorescent plate reader
(Biotek, Winooski, VT) at excitation 480 nm and emission 530 nm. Total protein
concentrations were measured by BCA protein assay kit (Pierce, Rockford, IL).
Quantification of intracellular lactate dehydrogenase (LDH) in the cell lysates was
used as an additional measure of cell growth. The assay was conducted as per
the manufacturer instruction (Caymen Chemical, Ann Arbor, MI).

MnSOD & FN ELISA
MnSOD ELISA was done [3] on cell lysate and tissue homogenate as per the
manufacturer instruction from a commercially available kit (abcam, Cambridge,
MA). Fifty µl sample is added to each pre antibody coated wells and sealed and
incubated for 2 hours at RT. Following 3 wash 50 µl detection antibody is added
to each well and incubated for 1 hour. After 3 more washes 50 µl of HRP
conjugate is added to each well and incubated another hour. Following 5 wash
100 µl developing solution is added and upon colour development 100 µl of stop
solution is added to each well. The plate is read at 450 nm using a plate reader
(Multiskan, Thermo Scientific, Burlington, ON). Total protein concentrations were
measured by BCA protein assay kit (Pierce, Rockford, IL). ELISA for FN was
performed using commercially available kits for human FN (Millipore, Billerica,
MA), rat FN (Kamiya Biomedical, Seattle, WA), mice FN (abcam, Toronto, ON)
according to the manufacturers’ instructions [15, 16]. The plates were read at 450
nm using a plate reader (Multiskan, Thermo Fisher, Canada).
Nuclear fraction isolation
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Nucleuar fractions were isolated from ECs and tissues as per the kit instruction
(Active Motif, Carlsbad, USA). Briefly media was aspirated out of the flasks and
washed with 5 ml ice cold PBS/Phosphatase Inhibitors. Another 3 ml of ice cold
PBS/Phosphatase Inhibitor solution was added to the cells. Cells were gently
scrapped and transferred to a pre chilled 15 ml conical tube and centrifuged for 5
minute at 500 rpm at 4OC. The cell pellet was resuspended in 500 µl 1X
hypotonic buffer and incubated on ice for 15 minute following mixing. Following
this 25 µl of detergent was added, vortexed and centrifuged at 14000 x g for 30
seconds at 4oC. The supernatant containing the cytoplasmic fraction was
separated following which the nuclear pellet was resuspended in 50 µl of
complete lysis buffer and vortexed for 10 seconds. Following 30 minute
incubation on ice on a shaker the suspension was centrifuged for 10 minutes at
14000 x g in a microcentrifuge precooled at 4oC. The supernatant containing the
nuclear fraction was collected [1, 3]. Fresh tissue sections were cut and weighed
washed in 3 ml (per gram tissue) ice cold 1X hypotonic buffer supplemented with
DTT and detergent and homogenized. Following incubation on ice for 15 minute
sample was centrifuged for 10 minute at 850 x g and pellet collected. Nuclear
extraction of the pellet was done as per the protocol of the cells described above.
Protein concentrations in the samples were measured by BCA protein assay
(Pierce, Rockford, IL).
FOXO1 DNA binding activity measurement
FOXO1 DNA binding ELISA was conducted [3] on the collected nuclear fraction
as per the manufacturer’s instruction (Active Motif, Carlsbad, CA). In short 10 ul
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diluted nuclear extract samples (2-20 ug protein concentration) were added to
oligonucleotide coated plates. The 96 well plate was sealed and incubated for 1
hr at room temperature following which the plate was washed 5 times with wash
buffer and 100 µl primary antibody (FOXO1) was added to each well. Following 1
hr of incubation at RT the plate was washed 5 times and 100 µl anti IgG HRP
conjugate antibody was added to each well. After 1 hr incubation plate was
washed 5 times and 100 µl developing solution was added to each well. As color
developed stop solution was added. The plates were read at 450 nm using a
plate reader (Multiskan, Thermo Fisher, Canada).
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